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Summary 
Nicotinic acetylcholine receptors (nAChRs) are considered as the founding father of 
the pentameric ligand-gated ion channel superfamily (Changeux, 2012), containing 
highly diverse family members. nAChRs are involved in the cholinergic transmission 
of the central nervous system, the peripheral nervous system, and at the 
neuromuscular junction. Based on their primary site of expression, nAChRs are 
broadly classified as muscle-type, neuronal-type, and non-neuronal and non-muscle 
type nAChRs. The muscle-type nAChRs are expressed at the neuromuscular 
junction, where it mediates the fast-synaptic response upon acetylcholine (ACh) 
release from the α-motor neuron. They are large glycoproteins of 290 kDa molecular 
mass. The adult subtype of the receptor is an asymmetric pentamer formed by four 
distinct subunits α1, β1, δ, and ε subunits in the ratio 2:1:1:1 and has two binding 
sites, one at the αδ interface and another at the αε interface. The receptor can exist in 
different states: closed, open and desensitized. It is one of the most studied ion 
channels and the gating mechanism has been described intensively. However, the 
reciprocal relationship between activation state and agonist binding is still elusive. 
Herein, we adapted a challenging approach called confocal patch-clamp fluorometry 
(cPCF) to study state-dependent agonist binding and unbinding behavior in nAChRs 
under whole-cell conditions. 
The main prerequisite for performing cPCF experiments was to find a suitable 
fluorescent agonist which can closely mimic the action of the native agonist 
acetylcholine and which functions in a concentration range suitable for fluorescence 
microscopy. For this reason, two other agonists of this receptor, nicotine, and 
carbachol, along with acetylcholine were functionally characterized and compared to 
find the best suitable ligand for synthesizing its fluorescent derivative. HEK 293 cells 
were used as the heterologous expression system. Functional characteristics such as 
concentration-response relationship, desensitization, recovery from desensitization 
and agonist-induced block were assessed and compared. Upon comparison, 
acetylcholine was found to be the most potent and efficient agonist for this receptor 
and was thus chosen for the synthesis of its fluorescent derivative. In this study, a 
novel fluorescence tagged ACh derivative, fACh, was identified which is an excellent 
congener of the native neurotransmitter agonist at adult muscle-type nAChRs. fACh 
was found to be similarly effective as ACh and even slightly more potent. Exposure of 
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transfected cells to fACh led to fluorescence signals that were absent in non-
transfected control cells.  
By performing cPCF recordings, allowing for monitoring agonist binding and channel 
gating in parallel, three different application approaches to gain more insight into the 
complex gating behavior of nicotinic receptors were suggested in the present study. 
1. Monitoring agonist binding and unbinding. Both agonist binding and unbinding 
followed a biexponential time course. Whereas the fast components were found to be 
too fast to be resolved, slow processes could be studied with cPCF. The existence of 
two components might support the idea of αδ and αε binding sites having different 
affinities for the agonist. 
2. Relating agonist binding to desensitization. When recording fluorescence intensity 
and current flow simultaneously, binding and desensitization behavior can be directly 
compared. Herein, a high similarity between the kinetics of binding and 
desensitization was found that supports the idea of an increase in binding affinity 
during desensitization.  
3. Relating unbinding to recovery from desensitization. cPCF allows for studying 
ligand unbinding during the electrically silent process of recovery. We found that 
recovery from desensitization was already completed, while the process of ligand 
unbinding was still proceeding. 
Together, the feasibility of employing fluorescent agonists to shed light on the 
activation mechanisms of the nAChRs and other members of the Cys-loop 
superfamily is demonstrated in the present study. 
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Zusammenfassung 
Nikotinerge Azetylcholinrezeptoren (nAChRs) werden häufig als Gründungsväter der 
pentameren ligandengesteuerten Ionenkanalsuperfamilie angesehen (Changeux, 
2012), eine vielfältig zusammengesetzte Gruppe ligandengesteuerter Ionenkanäle. 
Sie spielen eine wichtige Rolle in der cholinergen Transmission im zentralen und 
peripheren Nervensystem, sowie an der neuromuskulären Endplatte. Nach ihrem 
Expressionsort, werden sie in neuronale, muskuläre sowie nicht-neuronale/nicht-
muskuläre Rezeptoren eingeteilt. Der muskuläre nAChR an der postsynaptischen 
Membran der neuro-muskulären Endplatte vermittelt die schnellen synaptischen 
Antworten, ausgelöst durch Azetylcholinfreisetzung durch ein α-Motoneuron. Es 
handelt sich bei diesen Kanalproteinen um große Glykoproteine von 290 kDa 
Molekulargewicht. Die adulte Form ist ein asymmetrisches Pentamer, dass sich aus 
vier unterschiedlichen Untereinheiten zusammensetzt: α1, β1, δ, und ε im Verhältnis 
2:1:1:1. Es weist zwei Bindungsstellen auf, eine zwischen den Untereinheiten α1 und 
δ, die andere zwischen α1 und ε. 
nAChRs können in verschiedenen Aktivitätszuständen vorliegen: geschlossen, offen 
und desensitiviert. Obwohl es sich bei diesem Rezeptor um den am intensivsten 
untersuchten Ionenkanal handelt und der Aktivierungsmechanismus durch 
verschiedene experimentelle Ansätze beobachtet wurde, ist die reziproke Beziehung 
zwischen Agonistbindung und Aktivierungszustand nicht aufgeklärt. Eine geeignete 
Technik für diese Fragestellung ist die konfokale Patch-Clamp-Fluorometrie, eine 
Methode, die konfokale Fluoreszenzmikroskopie und Patch-Clamp-Techniken 
miteinander kombiniert, um mit Hilfe eines Fluorophor-markierten Agonisten 
Bindungs- und Aktivierungsverhalten parallel zu beobachten. In der vorliegenden 
Arbeit wurde die cPCF so modifiziert, dass sie für die whole-cell-Konfiguration unter 
Verwendung von HEK293-Zellen als heterologes Expressionssystem anwendbar ist. 
Eine wichtige Voraussetzung für die Anwendung der cPCF ist ein Fluorophor-
markierter Agonist, der eine ähnliche Wirkung hervorruft, wie der native Agonist 
Azetylcholin und in einem Konzentrationsbereich arbeitet, der für die Anwendung in 
der Fluoreszenzmikroskopie geeignet ist. Aus diesem Grund wurden zunächst drei 
Agonisten, Azetylcholin, Nikotin und Carbachol, funktionell charakterisiert, um deren 
aktivierendes Verhalten an adulten muskulären Rezeptoren in HEK293-Zellen unter 
whole-cell-Bedingungen zu studieren. Die Konzentrations-Aktivierungs-Beziehung, 
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das Desensitivierungsverhalten, die Erholung von der Desensitivierung sowie der 
Agonisten-induzierte Block wurden erhoben und verglichen. Azetylcholin hat sich als 
der am besten geeignete Agonist unter den drei getesteten herausgestellt und wurde 
daher als Agonist für die Fluorophor-Markierung herangezogen. Unterstützt durch 
Kooperationspartner (Plested-Labor, FMP Berlin und ChiroBlock GmbH Wolfen) 
wurde die Synthesestrategie entwickelt und realisiert. Wir konnten zeigen, dass das 
fluoreszierende Derivat (fACh) ähnlich effizient ist und eine geringfügig höhere 
Potenz im Vergleich zu ACh aufweist. Nach Applikation verursacht fACh an nAChR-
exprimierenden HEK293-Zellen ein spezifisches Fluoreszenzsignal, welches nicht in 
nicht-transfizierten Kontrollzellen auftrat. 
Durch die Anwendung der cPCF, die die parallele Beobachtung der 
Agonistenbindung und die damit in reziproker Beziehung stehende Kanalaktivierung 
erlaubt, konnten drei Applikationen vorgeschlagen werden, die zu einem besseren 
Verständnis des komplexen nAChR-Verhaltens beitragen können. 
1. Agonistenbindung und -entbindung. Sowohl die Agonistenbindung als auch die 
Entbindung folgte einem biexponentiellen Zeitverlauf. Während sich die schnelle 
Komponente als zu schnell erwies, um mit den hier verwendeten Methoden aufgelöst 
zu werden, konnte die langsame Komponente gut beschrieben werden. Das 
Auftreten zweier Komponenten könnte auf unterschiedliche Affinitäten der αδ- und 
αε- Bindungsstellen hindeuten, wie bereits aus früheren elektrophysiologischen 
Arbeiten vermutet. 
2. Beziehung zwischen Agonistenbindung und Desensitivierung. Durch die parallele 
Aufzeichnung der Fluoreszenzänderung und des Stromflusses können Bindungs-
verhalten und Desensitivierungsverhalten direkt miteinander in Beziehung gesetzt 
werden. Somit konnte in der vorliegenden Arbeit gezeigt werden, dass während der 
Desensitivierungsphase das Fluoreszenzsignal mit gleicher Kinetik ansteigt, was als 
Ausdruck einer desensitivierungsinduzierten Affinitätssteigerung interpretiert werden 
kann. Dies wurde auf Grund früherer elektrophysiologischer Arbeiten vermutet und 
kann nun direkt ausgelesen werden. 
3. Beziehung zwischen Agonistenentbindung und Erholung von der Desensitivierung. 
Die Anwendung der cPCF erlaubt es, Ligandenbindung auch an elektrophysiologisch 
nicht zu fassende Aktivitätszustände zu beobachten, wie sie zum Beispiel während 
 
XI Summary 
der Erholung von der Desensitivierung auftreten. In dieser Arbeit fanden wir eine 
kürzere Zeitkonstante für den Prozess der Erholung als für den Prozess der 
Agonistenentbindung. Dies könnte darauf hindeuten, dass eine erneute 
Kanalaktivierung bereits möglich ist, während die Entbindung des zweiten Liganden 
noch nicht abgeschlossen ist.  
Zusammenfassend konnte gezeigt werden, dass Fluorophor-gekoppelte Agonisten 
ein geeignetes Werkzeug sind, um mit Hilfe der konfokalen Patch-Clamp-
Fluorometrie unter Anwendung der whole-cell-Konfiguration den 
Aktivierungsmechanismus nikotinerger Azetylcholinrezeptoren zu untersuchen. Bei 
Vorhandensein geeigneter Agonisten kann diese Methode auf andere Cys-Loop-
Rezeptoren übertragen werden. 
 
  
 1 Introduction 
1. Introduction 
1.1. Acetylcholine receptors  
Acetylcholine receptors (AChRs) are integral membrane proteins, which respond to a 
direct binding of the ligand acetylcholine (ACh), and hence, are categorized as 
ligand-gated ion channels. In 1914, Sir Henry Dale classified two types of ACh 
receptors, metabotropic muscarinic ACh receptors and ionotropic nicotine ACh 
receptors. This distinction was based on the receptors’ sensitivities to different 
agonists: muscarine, a toxin from the mushroom Amanita muscaria and nicotine, an 
alkaloid found in leaves of Nicotiana tabacum, respectively. Both muscarine and 
nicotine mimic responses typical for ACh.  
The muscarinic type (mAChRs), a member of the G-protein coupled receptor 
(GPCRs) family, mediates its slow metabolic responses by activating a cascade of 
intracellular pathways whereas nicotinic receptors (nAChRs) are ligand-gated ion 
channels of the ‘Cys-loop’ superfamily that mediate fast synaptic responses. 
However, both receptors share the similar property of being activated by the 
endogenous ligand ACh and are expressed in both, neuronal and non-neuronal cell-
types. 
 
1.2. Nicotinic ACh receptors  
nAChRs are prototypes for the pentameric ligand-gated ion channels (Celie et al., 
2004). They are non-selective cation channels (Gündish and Eibl, 2012; Reitstetter et 
al., 1999) and are characterized by unique combinations of 17 homologous subunits, 
i.e. α1- α10, β1- β4, δ, ε, and γ (Lukas et al., 1999; Kalamida et al., 2007; Wu and 
Lukas, 2011; Gündish and Eibl, 2012). An evolutionary phylogenetic tree of nicotinic 
ACh receptor subunits is shown in Figure 1. 
Based on their primary site of expression, nAChRs are broadly classified as muscle-
type nAChRs, neuronal-type nAChRs, and non-neuronal / non-muscle type nAChRs. 
Muscle-type nAChRs are exclusively found at the neuromuscular junction and fetal 
extrajunctional sites (Lustig, 2006; Kalamida et al., 2007; Gündish and Eibl, 2012). 
Neuronal-type nAChRs are present in CNS, PNS, and ganglions (Gotti and Clementi, 
2004; Lustig, 2006; Kalamida et al., 2007; Gündish and Eibl, 2012), while non-
neuronal and non-muscle type are present in keratinocytes, bronchial epithelial cells, 
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aortic endothelial cells, macrophages, and lymphocytes (Lindstrom, 1997; Nguyen et 
al., 2000; Peng et al., 2004; Lustig, 2006; Kalamida et al., 2007; Gündish and Eibl, 
2012). 
 
 
 
Figure 1. An evolutionary phylogenetic tree of nicotinic ACh receptor subunits                  
The dendrogram illustrates the apparent evolutionary distance between subunits of the 
nicotinic ACh receptor. The ancestral or precursors of α-subunits (ligand binding subunits) 
and β-subunits (non-ligand binding subunits) were most probably homologs of nAChR α9 or 
α10 (adapted from Lustig, 2006). 
 
nAChRs subtypes mediate various important physiological, pathophysiological, and 
therapeutic functions (Lustig, 2006; Kalamida et al., 2007; Gündish and Eibl, 2012). 
They are involved in regulating the release of neurotransmitter, synaptic transmission, 
cell excitability, neuronal networking, and integrations as well as in regulating pain, 
hunger, anxiety, sleep, and arousal (Lindstrom, 1997; Changeux and Edelstein, 2001; 
Gotti and Clementi, 2004; Lustig, 2006). Impairment of nAChR function also leads to 
a variety of diseases and disorders, such as myasthenia gravis, Alzheimer's disease, 
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Parkinson disease, depression, schizophrenia, obesity, tobacco dependence, 
epilepsy, and some form of skin disorders (Lustig, 2006; Gündish and Eibl, 2012). 
1.3. Muscle-type nicotinic ACh receptors 
The muscle-type nAChR is a large glycoprotein of 290 kDa molecular mass (Francis 
and Papke, 1996; Prince et al., 2002; Unwin, 2005). It exists in an asymmetric 
pentamer formed by four distinct subunits, α1, β1, δ, and ε in the ratio of 2:1:1:1 
(Figure 2A). In fetal form, γ subunit is present instead of ε subunit (Auerbach, 2015). 
The receptor contains two binding sites: αδ and αε. These subunits assemble to form 
a pore that allows cations to cross the cell membrane. Each subunit exhibits a large 
N-terminal extracellular domain (Francis and Papke, 1996; Prince et al., 2002; Unwin, 
2005; Wonnacott and Barik, 2007), a membrane-spanning domain (Reynolds and 
Karlin, 1978; Lindstrom et al., 1979; Saitoh et al., 1980; Raftery et al., 1980; Kistler et 
al., 1982; Giraudat et al., 1982; Francis and Papke, 1996; Unwin, 2005; Wonnacott 
and Barik, 2007), and a smaller intracellular domain (Francis and Papke,1996; Prince 
et al., 2002; Unwin, 2005). 
 
 
 
Figure 2. Illustration of the heteropentameric muscle-type nAChR 
(A) The figure shows the arrangement of five subunits that form a pore, which allows the 
exchange of cations across the cell membrane. Circles in red and yellow represent the two 
binding sites at the αδ and αε interface, respectively. Each subunit is made up of four 
transmembrane domains shown in patterned circles. (B) The cartoon represents the putative 
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transmembrane organization of a single nAChR subunit. All four transmembrane domains 
(M1-M4) are represented.  
 
1.3.1. Molecular architecture of the muscle-type nicotinic ACh receptors 
The extracellular ligand binding domain of each nAChR subunit is organized around a 
curled β-sandwich consisting of two sets of β-sheets, which are joined via a disulfide 
bridge (Brejc et al., 2001). This disulfide bridge forms a so-called ‘Cys-loop’, the 
signature sequence of the ligand-gated ion channel family (Figure 3). Extracellular 
domains of nAChRs contain two ligand-binding sites: one at the αδ interface, while 
another at the αε interface (Prince et al., 2002). These sites allow for binding of 
ligands to the channel and mediate channel functions. However, the question is still 
to be addressed whether these two binding sites are identical (Colquhoun and 
Ogden, 1988; Akk and Auerbach, 1996; Salamone et al., 1999) or non-identical 
(Arias, 2000; Unwin, 2005; Kalamida et al., 2007; Wonnacott and Barik, 2007) 
concerning of ligand affinity. Each binding site is formed by the combination of two 
separate parts: one is called the ‘principal component’ (segments of α subunit) and 
the other is called the ‘complementary component’ (segments of non-α subunit). Two 
cysteine residues, Cys 128 and Cys 148 located in the α subunit (Torpedo) form a 
disulfide bridge that helps in agonist binding and channel opening (Wonnacott and 
Barik, 2007). While α1, δ, and ε subunits play a role in ligand binding, β1 helps in 
clustering of the nAChRs (Kalamida et al., 2007). Apart from full agonists (i.e. ACh), 
partial agonists (e.g., decamethonium), as well as competitive antagonists (e.g., α-
bungarotoxin) can also bind to the primary binding sites (αδ and αε) of the channel. 
However, there is another binding site(s) for non-competitive agonists (e.g., 
catharanthine) and allosteric modulators (e.g., galantamine) (Akk and Steinbach, 
2005; Wonnacott and Barik, 2007; Papke et al., 2010; Arias et al., 2010; Papke, 
2014).  
The membrane-spanning domain of each subunit of the nAChR is composed of four 
transmembrane α helical segments (M1-M4) (Unwin, 2005; Kalamida et al., 2007) 
(Figure 2B). The M2 segment of each subunit of the nAChR mainly contributes to the 
lining of the channel pore, while the extracellular ends of the M1 segment of each 
subunit possibly have a smaller contribution in the lining of the channel pore. 
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(Changeux et al., 1992; Arias, 1996; Miyazawa et al., 1999; Prince et al., 2002). 
Segments M1, M3, and M4 shield the inner ring formed by M2 α helical segments 
from membrane lipids by coiling around each other (Unwin, 2005; Kalamida et al., 
2007).  
The intracellular domain of each subunit of the nAChR consists of the large 
cytoplasmic M3-M4 loop containing a curved α-helix. The length of the loop is 
different for different subunits ranging from 110 to 270 amino acids. Intracellular loops 
possess an abundance of negatively charged amino acids that favor the influx of 
cations (Na+, K+, and Ca2+) (Unwin, 2005). 
 
 
 
Figure 3. Electron microscopy structure of a single subunit (α) of Torpedo marmorata 
nAChR at 4 Ao resolution  
Ribbon structure of a side view of the α subunit is illustrated. The transmembrane domains 
(M1-M4) are shown in yellow, β-sandwich are shown in red (outer) and blue (inner). 
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Functionally important A, B, C, β1- β2 and Cys loops are also represented. MA (yellow) is a 
curved α- helix present in intracellular domain (adapted and modified from Unwin, 2005). 
 
1.3.2. Gating behavior of muscle-type nicotinic ACh receptors 
Muscle-type nAChRs are allosteric proteins that exist in multiple interconvertible 
conformational states (Papke, 2014): resting or closed state, activated or open state, 
and desensitized states (Katz and Thesleff, 1957; Sakmann et al.,1980; Neubig et 
al.,1982; Heidmann et al., 1983; Jackson, 1989; Auerbach, 1993; Hess, 1993; Karlin 
and Akabas, 1995). However, the existence and an exact number of possible 
substates are still a matter of debate. The allosteric mechanism which leads the 
receptor to undergo conformational changes is known as gating (Perutz, 1989). The 
main functional states of adult muscle-type nAChRs are shown in Figure 4. 
 
 
 
Figure 4. Functional states of the adult muscle-type nAChR 
Illustrations of the different functional states: resting and unliganded, resting and liganded, 
activated, and desensitized state. In the absence of a ligand, the channel exists in the closed 
state (resting unliganded state). When a ligand binds to the receptor (resting liganded state), 
the gate of the channel opens due to conformational changes in the receptor. This is defined 
as an activated state. Upon prolonged exposure of the ligand, the channel enters into the 
desensitized state. The ligand is shown in green color. A horizontal gray bar in the channel 
lumen represents closure of the channel gate, the tilted gray bar represents a different 
conformation of the gate which does not allow passage of ions through the pore.  
 
The ‘resting’ or ‘closed state’ exists when the gate of the receptor is closed in the 
absence of ligands at the binding sites. The closed state is the most stable state, 
however, spontaneous openings without ligands being bound are possible to a low 
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extent (Karlin and Akabas, 1995; Karlin, 2002). Binding of ligands to the binding sites 
provokes the channel to undergo tertiary conformational changes, resulting in a 
metastable state called ‘open’ or ‘activated state’ (Kalamida et al., 2007). This leads 
to a movement of ions across the cell membrane. The transient opening of the 
channel occurs within tens of microseconds (Wu et al., 1994; Yamodo et al, 2010). 
However, prolonged presence of agonist at binding sites for hundreds of milliseconds 
triggers the channel to enter into a ‘desensitized state’. Amongst the liganded states, 
the desensitized state is the most stable state and has the highest affinity for ligands; 
howbeit, access of ions in the pore is prohibited (Karlin and Akabas, 1995; Karlin, 
2002). The channel enters into the closed state again when unbinding of ligands is 
completed. The stoichiometry of the receptor, types of ligands (agonists, antagonists, 
and allosteric modulators), and occupancy of binding sites regulate the equilibrium 
between different functional states (Papke, 2014). 
 
Resting state of the receptor 
The resting or closed state is a non-conducting state as there is no ionic movement 
across the channel due to the closure of the pore. Electron microscopic studies of 
Torpedo marmorata nAChRs at 4 Ao resolution revealed that the presence of bulky 
hydrophobic side chains and a smaller separation between M2 helices make the pore 
constricted enough that the passage of ions is hindered.  
 
 
 
 
Figure 5. Overview of the pore in the closed conformational state of the receptor 
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(A) The image represents the molecular surface of the pore domain. Circles in red and dark 
blue represent highly positively charged and highly negatively charged areas, respectively. 
Yellow circles show the hydrophobic area containing the gate of the pore. (B) The model 
represents symmetrical arrangements of side chains that form the gate of the channel. The 
blue sphere indicates a sodium ion in both A and B (adapted from Miyazawa et al., 2003). 
 
Additionally, side-to-side interactions of hydrophobic amino acids of neighboring M2 
helices form a tight hydrophobic girdle (Figure 5). Hence, the energetic barrier 
created by the girdle prevents the ionic permeation during resting state (Miyazawa et 
al., 2003). 
Open state of the receptor 
Ligand binding facilitates the conformational change in the receptor entering into the 
conducting or open state. It is interpreted that upon ligand binding, the two sets of β-
sheets in the α subunit exert alternative conformations facilitating the activation of the 
channel. This allosteric change entails 15o rotational movement of the inner β-sheets. 
The twisting movement weakens side to side hydrophobic interactions, which 
otherwise are responsible for the constricted pore. The helices ‘collapse’ back and 
make alternative hydrophobic contact with the outer protein wall. As a consequence, 
the channel skips to the ‘open state’ (Miyazawa et al., 2003) (Figure 6). 
 
 
 
Figure 6. Illustration of closed (left) and open (right) channel conformation 
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Binding of the ligand to the binding sites leads to a 15o rotational movement, which is 
transmitted to the gate via M2 helices. Rotation destabilizes the gate and leads the helices to 
adopt an alternative configuration where they can move freely, resulting in a weakening of 
side to side hydrophobic interactions. Consequently, helices collapse and lead to the opening 
of the ion channel. The relevant moving part is shown in gray. Arrows denote the alternative 
conformations of β-sheets. Pink patch on the left represents the gate. Broken horizontal gray 
lines display the membrane surface (adapted and modified from Unwin, 2003). 
 
Although the structural mechanism by which ligand binding leads to channel opening 
is known, it is still a matter of debate whether ligand binding at one binding site can 
open the channel (Jha and Auerbach, 2010; Williams et al., 2011) or two binding sites 
must be occupied for channel opening (Cash and Hess, 1980; Sine and Taylor, 1980; 
Stroud and Moore, 1985; Arias, 2000; Wonnacott and Barik, 2007). 
 
Desensitized state of the receptor 
Desensitization of nAChRs was first described by Katz and Thesleff in 1957. The 
desensitized state exists under kinetically distinguishable protein conformations 
(Heidmann and Changeux, 1980; Neubig and Cohen 1980; Reitstetter et al., 1999; 
Elenes and Auerbach, 2002; Elenes et al., 2006). It is a high-affinity albeit non-
conducting state that occurs spontaneously upon prolonged exposure to the agonists. 
Additionally, channels can also undergo desensitization without channel activation 
and thus by surpassing the open state (Magleby and Pallotta, 1981; Reitstetter et al., 
1999). Desensitization plays a key role in synaptic plasticity (Galzi and Changeux, 
1994; Reitstetter et al., 1999) and in nicotine dependence of smokers (Lukas et al., 
1996; Reitstetter et al., 1999). Inaccurate desensitization of the receptor leads to 
pathophysiological problems, such as myasthenia gravis and congenital myasthenic 
syndrome (Giniatullin et al., 2005; Kalamida et al., 2007). The duration of agonist 
application as well as the concentration of agonist, regulate the desensitization 
process (Wang and Sun, 2005).  
The receptor can exist in several different states of desensitization, but the exact 
number of states and their properties are still undetermined (Reitstetter et al., 1999; 
Elenes and Auerbach, 2002). Despite this fact, desensitization is often classified into 
two states: ‘fast’ and ‘slow’ (Neubig et al., 1980; Boyd and Cohen, 1980; Yu et al., 
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2009). The ‘fast’ or ‘classical desensitization’ follows the activation and occurs within 
tens of milliseconds. It generally takes place upon medium to high (µM to mM) 
concentrations of agonist application. However, ‘slow’ or ‘high-affinity desensitization’ 
takes place upon agonist application in nM to µM range and occurs in seconds to 
minutes range (Changuex and Edelstein, 1998; Dahan et al., 2004; Giniatullin et al., 
2005) (Figure 7). 
In comparison to activation, the mechanism of desensitization is poorly understood 
(Elenes and Auerbach, 2002; Giniatullin et al., 2005; Yu et al., 2009). Structural 
changes in the receptor during binding and activation has been nicely deduced 
(Unwin, 1995; Brejc et al., 2001), but locations and conformational changes that drive 
the channel into the desensitized state are still unclear. 
 
 
Figure 7. Different states of desensitization 
Classical desensitization is fast (in ms - s range) that occurs upon application of an agonist in 
the µM to mM range, whereas high-affinity desensitization is slow (in s-min range). It occurs 
upon application of an agonist in the nM to mM range (adapted from Giniatullin et al., 2005). 
 
Block of muscle-type nicotinic ACh receptors 
The block of the muscle-type nAChRs by barbiturates and local anesthetics was first 
reported by Adams (1976) and Ruff (1976). In addition to the antagonists, open 
channel block of nAChRs by agonists such as ACh, nicotine, carbamylcholine, 
suberyldicholine (Sine and Steinbach, 1984; Ogden and Colquhoun, 1985; 
Maconochie and Steinbach, 1995), decamethonium (Adams and Sakmann, 1978; 
Marshall et al., 1991), tetraethylammonium, tetramethylammonium (Akk and 
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Steinbach, 2003), and choline (Grossman and Auerbach, 2000; Purohit and 
Grossman, 2006; Lape et al., 2009) has been constantly reported.  
The mechanism behind the transient blocking of the receptor by agonists is still 
obscure. It is predicted that during the open channel block, the interruption in ionic 
flow is a result of physically plugging the pore by the open channel blockers (Prince 
et al., 2002), which hints towards the presence of an extra binding site inside the pore 
other than the two binding sites in the extracellular channel portion (Maconochie and 
Steinbach, 1995). This was concluded from the fact that the access to the binding site 
inside the pore is only possible when the channel is present in the activated state. 
The location of the binding site is predicted to lie within the membrane field (Prince et 
al., 2002). Removal of agonists from the pore site leads to unblocking (reopening), 
whereas removal from the classical binding sites leads to the closure of the channel 
(Neher and Steinbach, 1978). 
 
1.3.3. Agonists and antagonists of muscle-type nAChRs 
It is widely known that muscle-type nAChRs are activated upon binding of 
endogenous ligand ACh at binding sites located in the extracellular domain. 
Surprisingly, several other ligands can also bind to the same binding sites and 
regulate the gating of the nAChRs. Agonists, such as epibatidine, carbamylcholine, 
nicotine, and choline are substances, which upon binding to the receptor, activate the 
receptor to produce a biological response (Arias, 2000; Wonnacott and Barik, 2007). 
Unlike agonists, antagonists inhibit a biological response by binding to a receptor. 
They are commonly classified as competitive antagonists and non-competitive 
antagonists. Competitive antagonists, such as α-bungarotoxin, d-tubocurarine, α-
conotoxin MI, and lophotoxin bind at or near the agonist binding sites and compete 
with the agonists by preventing their access to the binding sites. Non-competitive 
antagonists or channel blockers, such as physostigmine, chlorpromazine, and 
galantamine are those which inhibit the function of the channel without inhibiting 
agonist binding. Their binding sites are located at different luminal and non-luminal 
domains (Arias, 2000; Wonnacott and Barik, 2007). Table 1 and Table 2 summarize 
various agonists, competitive antagonists, and non-competitive antagonists of 
muscle-type nAChRs (Cooper et al., 1996; Akk and Auerbach, 1999; Arias, 2000; 
Jonsson et al., 2006; Wonnacott and Barik, 2007; Kudryavtsev et al., 2015). 
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Table1: List of agonists of muscle-type nAChRs. 
 
Table 2: List of antagonists of muscle-type nAChRs. 
Antagonists Source of origin Comments 
α-Bungarotoxin Found in venom of the snake 
Bungarus multicinctus 
Competitive  
α-conotoxin MI Found in venom of the snail Conus 
magus 
Competitive 
d-tubocurarine Mono-quaternary alkaloid found in the 
Chondrodendron tomentosum plant 
Competitive 
Agonists Source of origin Comments 
ACh Motor neuron, parasympathetic 
nervous system 
Endogenous 
ligand 
Choline Plants and animal products Essential nutrient  
Nicotine Natural alkaloid found in plants of 
Solanaceae family  
Exogenous ligand 
Epibatidine Natural alkaloid secreted by 
Epipedobates frogs 
Exogenous ligand 
Cytisine Natural alkaloid found in plants of 
Fabaceae family 
Exogenous ligand 
Anatoxin-a Bicyclic amine alkaloid found in 
cyanobacteria 
Exogenous ligand 
Lobeline Natural alkaloid found in plants of 
Lobelia family 
Exogenous ligand 
Muscarine Natural alkaloid found in mushroom 
species Amanita muscaria 
Exogenous ligand 
Carbamylcholine Synthetic choline ester and a positively 
charged quaternary ammonium 
compound 
Exogenous ligand 
 
Dimethylphenylpiperazinium 
iodide 
Synthetic compound Exogenous ligand 
Oxotremorine-M Synthetic compound Exogenous ligand 
Methacholine Synthetic choline ester Exogenous ligand 
Succinylcholine Synthetic compound Exogenous ligand 
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Coniine An alkaloid found in Conium 
maculatum plant 
Competitive 
Pinnatoxins  A toxin derived from a dinoflagellate 
Vulcanodinium rugosum 
Competitive 
Lophotoxin A neuromuscular toxin isolated from 
corals of Lophogorgia genus 
Competitive 
Decamethonium A synthetic bis-quaternary ammonium 
compound  
Competitive 
Parncuronium An amino steroid Competitive 
Benzoquinonium Synthetic compound Competitive 
Physostigmine A crystalline alkaloid obtained from 
Calabar bean 
Non-competitive 
Galantamine A tertiary alkaloid obtained from plants 
of Amaryllidaceae family 
Non-competitive 
Histrionicotoxin A poisonous alkaloid found in the skin 
of frog Oophaga histrionica 
Non-competitive 
Chlorpromazine An antipsychotic drug; synthetic  Non-competitive 
 
 
1.3.4. Physiological aspect of nAChRs at neuromuscular junction 
A motor neuron and a motor endplate with a synaptic cleft (junctional gap) form a 
neuromuscular junction, which plays a key role in the contraction of skeletal muscles. 
nAChRs concentrated in the sarcolemma at the neuromuscular junction (Unwin, 
2005) are involved in transferring the electrical impulses of α-motor neurons to 
muscle cells.  
When the action potential reaches the nerve terminal, it depolarizes the terminal, 
which accelerates the opening of voltage-gated calcium channels. This leads to an 
increase in the intracellular calcium concentration, which triggers the release of ACh 
molecules from the axon terminal to the synaptic cleft. ACh molecules bind to 
nAChRs present at the motor endplate. Binding of ACh results in the opening of 
nAChRs, which leads to the inward current due to the movement of cations, and 
hence, the membrane gets depolarized. This depolarization causes opening of the 
voltage-gated sodium channels that result in eliciting action potentials. Elicited action 
potentials propagate along the sarcolemma and membrane of the T-tubules. This 
 14 Introduction 
triggers the release of stored calcium from the sarcoplasmic reticulum and ultimately 
leads to muscle contraction (Figure 8). When the calcium concentration returns to the 
normal level, it induces muscle fibers to relax (Slater, 2017). 
 
 
Figure 8. Events at the neuromuscular junction. 
When action potentials reach the axon terminal: (1) ACh gets released and binds to the 
nAChRs present at the motor endplate. (2) Binding of ACh to nAChRs results in the opening 
of nAChRs. This leads to inward movement of cations that results in the generation of 
transient endplate potential and opening of voltage-dependent sodium channels. Opening of 
voltage-gated sodium channels results into elicitation of action potentials in the muscle fibers. 
These action potentials further propagate to the T-tubules. (3) In response to the transient 
voltage change, Ca2+ gets released from the sarcoplasmic reticulum and triggers muscle 
contraction (modified from Molnar and Gair, 2015).    
 
1.3.5. Pathophysiological aspect of muscle-type nAChRs 
Muscle-type nAChRs are eminent targets in several acquired and inherited diseases, 
such as myasthenia gravis and congenital myasthenic syndromes that cause 
impairment of neuromuscular transmission and muscle weakness (Kalamida et al., 
2007).  
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Myasthenia gravis is a chronic autoimmune disorder in which autoantibodies are 
produced by white blood cells, which bind to the body’s own muscle nAChRs and 
destroy them. Muscular weakness caused by the reduced efficiency of the 
neuromuscular junction and fatigue are symptoms of this disease. It can either be 
confined to a single muscle group or can be spread to several skeletal muscles 
(Kalamida et al., 2007). 
Congenital myasthenia syndrome is an inherited disease caused by defective genes 
resulting in muscle fatigue due to deformity at the neuromuscular junction. Some of 
the naturally occurring ‘gain of function’ mutations, such as αG153S, αN217K, and 
εL221F in adult human muscle-type nAChRs are well-known (Engel et al., 1982; 
Oosterhuis et al., 1987; Engel et al., 1996; Abraham, 2003), which cause the 
congenital myasthenic syndrome. This syndrome is generally classified into two 
subtypes: slow channel syndromes and fast channel syndromes. These slow and fast 
channel syndromes are characterized by kinetic abnormalities of nAChR function. 
Slow channel syndromes arise due to the prolonged opening of the nAChR channel, 
causing abnormally slow decay of the synaptic currents. In contrast, fast channel 
syndromes arise from the abnormally fast decay of synaptic response because of 
brief channel opening due to decreased affinity for ACh and lower gating efficiency 
(Kalamida et al., 2007).  
Another reason why muscle-type nAChRs involved in neuromuscular transmission 
are of pharmacological interest is their usability as an appropriate pharmacological 
target for muscle relaxants, such as rocuronium, rapacuronium, and 3-desacetyl 
rapacuronium (Paul et al., 2002). Muscle relaxants, in particular, neuromuscular 
blocking agents, work at the neuromuscular junction. They are basically classified as 
depolarizing blocking agents (e.g., succinylcholine) and non-depolarizing blocking 
agents (e.g., tubocurarine). Depolarizing agents are agonists that mimic ACh, while 
non-depolarizing agents competitively block or inhibit ACh binding to the nAChR. 
These muscle relaxants are co-administered with anesthesia during surgery to cause 
temporary paralysis. 
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2. Aim and objectives of the study 
Many functional studies are committed to determining whether there are intermediate 
states between ligand binding and muscle-type nAChRs opening and between the 
opening and full desensitization. Complex kinetic models have been repeatedly 
proposed based on electrophysiological studies of muscle-type nAChRs to 
understand state-dependent relationships. Four examples are shown in Figure 10. 
 
 
 
Figure 10. Schemes of kinetic models 
(A) Kinetic model proposed by Grosman and Auerbach, 2001. C is the closed state, A is an 
activated state, O is an opened state, and D is a desensitized state. (B) The kinetic scheme 
proposed by Edelstein et al., 1996. B is a basal state (closed state), A is an active state, I is 
an initially inactivated state, and D is a desensitized state. (C) Illustration of a Monod-Wyman-
Changeux (MWC) model for desensitization proposed by Lester, 2014. R is a resting state, A 
is an activated state, O is an open state, D is a desensitized state, and I is a structurally 
distinct state of desensitization. (D) Kinetic model proposed by Lape et al., 2009. R is a 
resting state, F is a flip state (intermediate state), O is an open state, and D is a desensitized 
state. 
Although much is known about the structural and functional relationship of the 
receptor, the reciprocal relationship between ligand binding and channel gating is still 
elusive. Therefore, the aim of this study is to contribute to a further validation of these 
kinetic models so far based on electrophysiological recordings, by providing data on 
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ligand binding. For realizing this, adapting confocal patch-clamp fluorometry to whole-
cell recording was required. The objectives of the present study are: 
1. To accomplish experimental requirements for electrophysiological and/or 
fluorescent experiments. 
2. To find a suitable ligand amongst available agonists for synthesizing its 
fluorescent derivative. 
3. To synthesize the suitable fluorescent derivative. 
4. To relate ligand binding and gating for the synthesized fluorescent derivative. 
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3. Materials and Methods 
3.1. Plasmids amplification, extraction, and purification 
Genes encoding adult human muscle-type nicotinic ACh receptor (nAChR) α1, β1, δ, 
and ε in the plasmid vector pcDNA3 (generous gift by Lucia Sivilotti, UCL, London) 
were used in experiments of the present study. Plasmids were amplified in E. coli, 
extracted, and purified by Karin Schoknecht, Dr. Gunter Ehrlich, and Prof. Dr. 
Thomas Zimmer (Institute of Physiology II, Jena, Germany).  
 
3.2. Cell culture and transfection 
3.2.1. Cell line 
HEK 293 cells were used as a heterologous expression system. These cells are 
widely used in patch-clamp electrophysiology not only because they exhibit few 
endogenous channels but also because they have beneficial properties, such as a 
rapid division and easy maintenance. Furthermore, they can be transfected 
conveniently. The appropriate size of cells (about 20-30 µm in diameter) makes them 
suitable for the experimental needs of the present study.  
 
3.2.2. Cell culture 
HEK 293 cells (European Collection of Authenticated Cell Cultures, England) were 
initially grown in Petri dishes (100 x 20 mm; Greiner bio-one GmbH, Frickenhausen, 
Germany) and were maintained in Minimum Essential Media (MEM) with Earle’s Salt 
and L-Glutamine (GIBCO BRL, Karlsruhe, Germany) containing 10% Fetal Calf 
Serum (FCS) (Biochrom GmbH, Berlin, Germany), 1% antibiotics 
(penicillin/streptomycin), and 1% non-essential amino acid in a humidified 5% CO2 
incubator at 37oC. After achieving about 80-90 % cell confluence, cells were sub-
cultured using Trypsin-EDTA (GIBCO, BRL, Karlsruhe, Germany) digestion.  
 
3.2.3. Cell transfection 
3.2.3.1. Calcium phosphate transfection method 
HEK 293 cells were transiently transfected with calcium phosphate transfection 
method. The method is efficient for introducing foreign DNA plasmids in different cell 
types. The principle involves the introduction of DNA into cells by formation of a 
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calcium phosphate DNA co-precipitate. These precipitates are internalized by the 
cells via endocytosis leading to efficient expression of DNA (Graham and van der Eb, 
1973). 
 
3.2.3.2. Transfection procedure  
Cells were trypsinized, diluted with culture medium and were seeded in a separate 
Petri dish (60 x 15 mm; Greiner bio-one GmbH, Frickenhausen, Germany), for 
overnight incubation. Next day, when 60-70% of cell confluence was achieved, the 
culture medium was exchanged with fresh medium 1 hour before transfection. 
Plasmids of adult human muscle-type nAChRs α1, β1, δ and ε were mixed in a ratio of 
2:1:1:1, along with a CFP (cyan fluorescent protein) encoding plasmid (Clontech 
Laboratories, Inc. / Takara Bio, California, USA) as a cell transfection marker. A 
mixture of plasmids was then mixed with calcium chloride (CaCl2) solution, borate 
buffered saline (BBS, pH 6.95) and water in a definite proportion, vortexed and 
incubated for  10 minutes at room temperature. After 10 minutes, the solution was 
poured evenly over the cells, which were incubated afterward in a temperature 
controlled humidified CO2 incubator overnight.  
After 12-14 hours of transfection, the culture medium was aspirated, and cells were 
washed three times with PBS to remove traces of transfection solution remaining 
after aspiration that may otherwise lead to toxic effects. Cells were re-trypsinized, re-
diluted in culture medium and plated on coverslips coated with poly-l-lysine 
(0.5mg/ml) (Sigma-Aldrich Production GmbH, Steinheim, Germany) and placed in 24-
well plates. Electrophysiological experiments were performed after one day of 
transfection.  
 
3.2.3.3. Stoichiometry of adult muscle-type nAChRs 
Numerous studies showed that adult muscle-type nAChRs exist in a 
heteropentameric form consisting of α, β,  δ, and ε  subunits in a 2:1:1:1 ratio (Gupta et 
al., 2016; Albuquerque et al., 2009). However, the formation of the functional receptor 
has also been reported when oocytes were injected with mRNA or cRNA of α, β, δ and 
ε  subunits in a 1:1:1:1 ratio (J.Connolly et al., 1992; Yuan Liu and Paul Brehm, 1993; 
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HS Kachel et al., 2016). Therefore, an experiment was conducted to compare 
functional properties of the receptor in both cases. 
HEK 293 cells were transfected with two different subunit ratios: α, β, δ and ε  subunits 
in 2:1:1:1 ratio and in 1:1:1:1 ratio, respectively. Both transfections were done at the 
same time and on the next day, electrophysiological experiments were performed at 
both conditions. Cells were held at a potential of -60 mV and acutely exposed to          
500 µM ACh in order to record transient inward ionic currents (for more details about 
the electrophysiological settings see below) (Figure 11A).   
 
 
 
Figure 11. Influence of different plasmid ratios on the functional properties of the 
nAChR 
(A) Representative current traces obtained from cells transfected with plasmid ratios 2:1:1:1 
(light-blue) and 1:1:1:1 (dark-blue). Gray bar represents the period of ligand application (500 
µM ACh). (B) Comparison between maximum current amplitude (Imax) obtained with different 
plasmid ratios. The difference in the maximum current amplitude obtained from the two-
different plasmid ratios turned out to be insignificant (P=0.53). Black symbols represent 
means of 4 recordings (2:1:1:1 ratio) and 5 recordings (1:1:1:1 ratio), open symbols represent 
individual recordings. (C) Bar graph representing time course of desensitization, τdesensitization 
(ms) obtained with two different plasmid ratios. No significant difference was found in the time 
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course of desensitization obtained from the two different plasmid ratios (P=0.96). Data are 
means ± S.E.M. of 4-5 cells.  
Using 500 µM ACh, cells transfected with plasmids in the ratio 2:1:1:1 produced 
maximum current amplitude of 4.78 ± 0.62 nA (n=4) while those transfected with 
plasmids in the ratio 1:1:1:1 produced 7.55 ± 1.07 nA (n=5; P=0.62) (Fig. 11B). 
Further, receptor desensitization was fitted with a mono-exponential function in both 
cases. The time constants τdesensitization  were 194.85 ± 21.96 ms (n=4) for 2:1:1:1 
plasmid ratio and 193.58 ± 13.92 ms (n=5; P=0.96) for 1:1:1:1 plasmid ratio (Figure 
11C), respectively. Hence, functional properties of the receptor were found to be 
similar in both cases, indicating normal functioning of channels irrespective of the 
plasmid ratio. 
 
3.3. Chemicals and Solutions 
Ligands used to activate adult human muscle-type nAChRs were ACh chloride, 
nicotine, carbamylcholine chloride (all from Sigma-Aldrich Chemie GmbH, Steinheim 
Germany), and fACh, a fluorescent derivative of ACh (Chiroblock, Wolfen, Germany, 
Abcam, Cambridge, UK). Precursor compounds, i.e., chemically modified ACh 
derivatives, were provided by the Plested lab (FMP, Berlin). Stock solutions of a 
concentration of 50 mM were prepared in distilled water for all ligands and were 
stored at -20oC. Solutions of desired concentration were obtained by diluting 
respective stock solution in control solution used for patch-clamp experiments. All 
chemicals used were of analytical grade. 
Solutions used in patch-clamp experiments contained: 
External bath solution (extracellular solution) (in mM): 115 NaCl, 30 KCl, 1 MgCl2, 1.8 
CaCl2, 5.5 Glucose, 10 HEPES; pH 7.4 
Internal or pipette solution (in mM): 0.5 NaCl, 115 KCl, 1 MgCl2, 1.8 CaCl2, 5.5 
Glucose, 10 HEPES; pH 7.2 
Control solution (vehicle control for ligands) (in mM): 150 NaCl, 2 KCl, 10 EGTA, 10 
HEPES; pH 7.2 
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3.4. Patch-clamp experiments 
3.4.1. Fabrication of patch-pipettes 
Patch pipettes used for whole-cell patch clamp experiments were fabricated from 
borosilicate glass capillary tubes with an outer diameter and inner diameter of 2 mm 
and 1 mm, respectively (Hilgenberg GmbH, Malsfeld, Germany). Pipettes were pulled 
using a horizontal P-97 Flaming/Brown type micropipette puller (Sutter Instruments, 
Novato, USA) and were further fire polished with the help of an MF-830 Microforge 
fire-polisher (Narishige International USA, INC., New York, USA). Pipette resistance 
obtained after fire polishing was between 1-3 MΩ.  
Patch pipettes used for confocal whole-cell patch-clamp fluorometry experiments 
were fabricated from filament-containing borosilicate glass capillary tubes (A-M 
Systems, Sequim, Washington, USA) with an outer and inner diameter of 1.5 mm and 
1.12 mm, respectively, using a horizontal P-97 Flaming/Brown type micropipette 
puller (Sutter Instruments, Novato, USA). Pipette resistance was between 1-3 MΩ. 
Non-fire polished pipettes were used in these experiments. Specific reasons behind 
using different glass pipettes and avoiding fire polishing, in this case, are explained in 
the result section (refer 4.5.2). 
For ligand application, double-barreled theta glass capillaries (Hilgenberg GmbH, 
Malsfeld, Germany) were fabricated using a P-97 Flaming/Brown type micropipette 
puller (Sutter Instruments, Novato, USA). Polyethylene tubes (Adtech Polymer 
Engineering LTD, Stroud, Glos, England) of an inner diameter of 0.3 mm, an outer 
diameter of 0.76 mm, and a length of around 2-3 cm were inserted in both barrels at 
the non-fabricated end of the application pipette and were tightly sealed by glue. 
 
3.4.2. Patch-clamp recordings 
The patch-clamp technique is a standard electrophysiological technique that allows 
for measuring ionic currents through channel proteins with high time-resolution, 
providing the advantage to study the physiological and pathophysiological functions 
of ion channels in excitable cells or tissues.  
For basic electrophysiological experiments, the patch-clamp setup consisted of the 
following components: (1) an inverted microscope (Axiovert 100, Carl Zeiss 
MicroImaging GmbH, Jena, Germany) for cell visualization placed on a vibration-
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isolation table (Newport, Irvine (CA), USA), (2) a Faraday cage, surrounding the 
setup, which isolates the system from electrical noise, (3) a patch-clamp amplifier 
(Axopatch 2B, Axon Instruments Inc., Foster City (CA), USA) controlled by the patch-
clamp software ISO3 (MFK, Niederhnhausen, Germany) on a PC, (4) a 
micromanipulator (Luigs & Neumann Feinmechanik und Elektrotechnik GmbH, 
Ratingen, Germany) holding the amplifier head stage in connection with the pipette 
holder and the pipette, (5) CFP Filter set : BP 436/20 and 455 LP (Carl-Zeiss GmbH, 
Jena, Germany),              (6) halogen lamp to visualize transfected fluorescent cells, 
(7) a piezo device (Physik Instrumente (PI) GmbH & Co. KG, Karlsruhe, Germany), to 
switch the application pipette forth and back, (8) a bath chamber, (9) ) a piezo-driven 
application system for the application of ligands (tailor-made at the workshop of 
Institute of Physiology II, Jena, Germany), (10) a reference or bath electrode made of 
Ag/AgCl (Science Products GmbH, Hofheim, Germany), to set the zero current level 
that enables to observe changes in current while keeping the voltage constant, and 
(11) a recording electrode (Ag/AgCl wire) that allows electrical contact between the 
intracellular environment and the patch-clamp amplifier. 
Voltage-clamp experiments were performed in the whole-cell mode with a slight 
modification to allow fast solution exchange across the cell membrane (discussed in 
result section 4.1). To attain a gigaseal between glass pipette and cell membrane, the 
pipette was brought into close contact with the cell and negative pressure was gently 
applied using a 5 ml syringe. Once a gigaseal was obtained, cells were ruptured by 
using the zap function of the amplifier which injects a large amount of current into the 
cell resulting in opening the membrane patch underneath the pipette tip. This 
provided access to the intracellular side of the cell, leading to the attainment of the 
whole-cell mode. Cells were then lifted-up and positioned in front of the double-
barreled application pipette controlled by a piezo-device. Fast switches of this 
application pipette filled with control solution in one tube and ligand-containing 
solutions in the other tube were used to realize fast concentration jumps to the cell 
(Figure 12). This caused channel gating and resulted in the generation of ionic 
current. All recordings were done at -60 mV. Currents recorded were sampled at 5 
kHz and filtered at 2 kHz.  
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Figure 12. Patch clamp setup illustration  
Scheme of an electrophysiological setup with a lifted HEK 293 cell in front of a double-
barreled application pipette containing ligand and control solution is shown. A transfected 
HEK 293 cell (in blue; transfection marker: CFP) was lifted after attaining whole-cell 
configuration. Currents were recorded by a patch clamp amplifier.  
 
To measure the speed of the fast switching between the solutions, HCN2 
(hyperpolarization-activated cyclic nucleotide-gated channels) channels were used as 
a test system because these channels are voltage-activated and no ligand application 
is needed to activate the channel, which might have compromised the recording due 
to the binding of ligand. HCN2 channels expressed in HEK 293 cells were activated 
by applying a hyperpolarizing voltage pulse of -100 mV from a holding voltage of 0 
mV. Fast jumps were realized between 100% and 10% permeating cation solution. 
The estimated solution exchange time (10%-90%) is 6.8 ms. (Figure 13).  
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Figure 13. Monitoring of the speed of the solution exchange using piezo controlled 
application system. 
HCN2 channels expressed in HEK 293 cells were activated by applying hyperpolarizing 
voltage jumps from 0 to -100 mV. A representative current trace obtained in response to fast 
concentration jumps realized between 100% (150 mM KCl) and 10% (15 mM KCl) 
permeating cation solution is shown. The rise time from 10% to 90% is 6.8 ms. 
 
3.4.3. Confocal patch-clamp fluorometry  
Confocal patch-clamp fluorometry (cPCF) is a combination of electrophysiological 
patch-clamp and confocal fluorescence microscopy. It enables simultaneous 
electrical and optical measurements that allow either monitoring conformational 
changes in real-time or monitoring ligand binding by either using fluorescently tagged 
receptors or fluorescently tagged ligands. 
For cPCF, the standard electrophysiology set up can be used. Additional features of 
the setup were: (1) Confocal microscope (LSM 7 Duo+ LSM 710 scan head, Carl-
Zeiss Microscopy GmbH, Jena, Germany); (2) C-Apochromat 40x water-immersion 
objective (Carl-Zeiss Microscopy GmbH, Jena Germany); (3) He/Ne 543 laser line, to 
excite fACh; (4) He/Ne 633 laser line, to excite the reference dye Dy647 (Dyomics 
GmbH, Jena, Germany); (5) Zen 2010 fluorescence imaging software (Carl Zeiss 
Microscopy GmbH, Jena, Germany). 
For performing experiments, patch pipettes were adjusted around 45o with respect to 
the bath chamber and the whole-cell configuration was achieved using 25x (NA=0.8) 
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Plan-Apochromat water immersion objective (Carl-Zeiss Microscopy GmbH, Jena, 
Germany). When whole-cell mode was obtained, cells were lifted-up and positioned 
in front of the double-barreled piezo-driven application pipette (refer Figure 12). After 
positioning, the objective was switched to 40x (NA=1.2) C-Apochromat water 
immersion objective (Carl-Zeiss Microscopy GmbH, Jena, Germany) for imaging. 
Fast solution exchange was realized with the help of forth and back jumps of the 
application pipette between fACh and control solution. Both solutions contained 1 µM 
of the reference dye, Dy647, (1) for focusing the cell and (2) also used in the 
mathematical analysis to subtract the background fluorescence caused by unbound 
fACh, from the channel-bound fraction (refer section 3.6). 
Ionic currents were recorded at a membrane potential of -60 mV. The sampling rate 
was 10 kHz and the filter was set to 2 kHz. Optical measurements were performed 
simultaneously in the same cell. fACh and Dy647 dye were excited by the He/Ne 
laser lines 543 nm and 633 nm, respectively. The possibility of cross-talking between 
both dyes was neglectable because of their different absorption and emission 
spectra. The confocal slice thickness was 2 µm. 
Change in fluorescence intensity during the ligand binding phase as well as during 
the wash-out phase was recorded. Obtained fluorescence data points were sampled 
with different sampling rates of 10 Hz and 1.3 Hz (The reason for choosing two 
different sampling rates is discussed further in results section 4.5.4.). All experiments 
in the present study were performed at 20-22°C.  
 
3.5. The strategy for the synthesis of fluorescent ACh derivatives  
ACh derivatives were synthesized with the help of collaborators in Berlin, Germany 
(Dr. Andrew J.R. Plested, Molecular Neuroscience, and Biophysics group, Medicinal 
Chemistry group, Leibniz- Institute of Molecular Pharmacology, Berlin, Germany and 
Dr. Vera Martos, Medicinal Chemistry group, Leibniz- Institute of Molecular 
Pharmacology, Berlin) along with the companies ChiroBlock GmbH (Bitterfeld-
Wolfen, Germany) and Abcam (Cambridge, UK). The goal was to synthesize a 
fluorescent ligand for adult muscle-type nAChR which could closely mimic the action 
of its native ligand ACh. The basic approach was to couple a fluorophore to ACh via a 
linker, to avoid hindrance at the binding site as well as to retain the properties of the 
parent ligand (Baker et al., 2003; Middleton and Kellam, 2005; Middleton et al., 2007) 
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(Figure 14). It has been reported that the nature of the linker and the fluorophore, as 
well as the length of the linker, plays a key role in influencing the pharmacological as 
well as physicochemical properties of a parent ligand (Baker et al., 2010 and Rose et 
al., 2012). Therefore, choosing appropriate linkers and fluorophores was a key step 
for the strategy.  
 
 
 
Figure 14. The strategy to synthesize the fluorescent ACh derivative 
To synthesize a fluorescent derivative of ACh, the coupling of a suitable fluorophore to ACh 
via a linker was designed to avoid steric hindrance, which may be caused by the fluorophore 
when it is linked directly to ACh.  
 
Since polyethylene glycol (PEG) is hydrophilic, non-toxic, and non-immunogenic, it 
was chosen as a linker in the present study. A cyanine dye was used as fluorophore 
because cyanine dyes are comparatively small, photostable, bright, and cause 
minimal interruption with biological samples (Leisle et al., 2016). The fluorescent ACh 
derivative (fACh) was obtained as a final product by coupling the cyanine dye to ACh 
via a PEG linker. 
 
3.6. Data acquisition and analysis 
Electrophysiological data extracted from the ISO3 software were analyzed using 
Microsoft Excel 2010 and Origin 9.5 (OriginLab, Northhampton, USA). For 
fluorescence measurements, Zen 2010 fluorescence imaging software (Carl Zeiss 
Microscopy GmbH, Jena, Germany) was used. Imaging data were processed and 
analyzed using FIJI (Schindelin et al., 2012) (Java-based image processing program 
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inspired by National Institutes of Health), Microsoft Excel 2010 and Origin 9 
(OriginLab, Northhampton, USA) software.  
3.6.1. Electrophysiological data 
Concentration-activation relationship curves were constructed by normalizing the 
current amplitude (I) obtained at successive concentrations of ligands with respect to 
the maximum current amplitude (Imax) obtained at the saturating concentration of 
ligands and were plotted as a function of ligand concentrations (x). The mean 
concentration-activation data were fitted with the Hill equation, which provides an 
estimate of EC50, the concentration at which 50% of the channels are activated, and 
the Hill coefficient H, describing the slope of the curve (equation 1). 
 
𝑰𝑰 𝑰𝑰𝒎𝒎𝒎𝒎𝒎𝒎⁄ =  𝟏𝟏 [𝟏𝟏 + (𝑬𝑬𝑬𝑬𝟓𝟓𝟓𝟓 𝑨𝑨⁄ )]⁄ H                                                                                             
(1) 
 
where I is the current amplitude, A the concentration of the agonist, EC50 the 
concentration of the ligand that produces a half-maximal response, and H the Hill 
coefficient. Unless otherwise stated, Imax was constrained to 1 because a maximal 
ligand concentration was used to define full ligand activity. 
 
Desensitization kinetics and recovery from desensitization were analyzed with either 
a mono-exponential (equation 2) or a bi-exponential (equation 3) function based on 
curve fitting using Origin 9.5 (Origin Lab, Northampton, USA). To analyze the rate of 
onset of desensitization, the current data points were fitted from the point after the 
peak current was reached until the end of ligand application period.  
 
The mono-exponential function is defined as: 
 
𝒚𝒚 = 𝒚𝒚𝟓𝟓 + 𝑨𝑨𝑨𝑨−𝒎𝒎 𝝉𝝉𝟏𝟏⁄                      (2) 
 
where yo is the offset, A is the amplitude and τ is the decay time constant.     
 
The bi-exponential function is defined as: 
 
𝒚𝒚 = 𝒚𝒚𝟓𝟓 + 𝑨𝑨𝟏𝟏𝑨𝑨−𝒎𝒎 𝝉𝝉𝟏𝟏⁄ + 𝑨𝑨𝟐𝟐𝑨𝑨−𝒎𝒎 𝝉𝝉𝟐𝟐⁄                                                                                      (3) 
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where yo is the offset, A1 and A2 are the amplitudes for two different desensitization 
components. τ1 and τ2 are the respective decay time constants. 
3.6.2. Image analysis 
Confocal images obtained with the ZEN 2010 fluorescence imaging software were 
analyzed using the JAVA-based image processing software FIJI (ImageJ) (Schindeln 
et al., 2012).  
The fluorescence intensity caused by fACh binding to the nAChR expressing cells 
was collected from an individual whole cell. Because cells were not perfectly stable in 
shape when flushed by the solution stream, a fixed region of interest (ROI) was not 
appropriate for time series analysis. Therefore, we used a high number of line 
profiles, integrated the fluorescence signals per line and summed them up. Figure 15 
shows an exemplary image with three profiles. At least ten profiles were used per 
image. 
 
 
 
Figure 15. Image analysis 
(A) Confocal image of a cell recorded 50 ms after being exposed to 10 µM fACh. The cell 
was attached to a patch pipette, lifted from the chamber bottom and positioned within the 
solution stream. Red lines indicate profiles used for analysis. (B) Fluorescence intensities 
along the red lines in (A). 
 
In case of ligand application intervals, when fACh was also labeling the bath solution, 
a reference dye Dy647 was used for background subtraction (Biskup et al., 2007). 
Dy647 was not binding to the receptor or somewhere else on the cell surface (refer 
Figure 43) so that it behaved like unbound fACh, thus making it a good marker for 
background subtraction.  
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3.7. Statistical analysis 
All data points are expressed as mean ± S.E.M. Statistical comparisons were done 
with Student’s t-test and a P < 0.05 was considered as significant. 
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4. Results 
Adult muscle-type nAChRs can exist in three interconvertible conformational states, 
i.e. closed, open or desensitized state (Katz and Thesleff, 1957; Krauss et al., 2000; 
Zouridakis et al., 2009, Papke, 2014). Numerous studies (Miyazawa et al., 2003; 
Purohit et al., 2007; Wells, 2008; Albuquerque et al., 2009, Unwin, 2013) have 
provided a clear understanding of receptor structure and mechanism of ligand 
binding. In the last decades, various approaches, such as time-resolved 
photolabeling (Averalo et al., 2005), incorporation of unnatural amino acids (Nowak et 
al., 1995), and variant fluorescence techniques (Dahan et al., 2004; Grandl et al., 
2007; Fujimoto et al., 2008) have been applied to study the state-dependent 
structure-function relationship of nAChRs, however, a clear concept is still missing. 
Therefore, the present study is dedicated to the simultaneous investigation of ligand 
binding and channel gating in adult muscle-type nAChRs using an approach called 
confocal patch-clamp fluorometry (cPCF).  
To investigate ligand binding and channel gating employing cPCF, prerequisites were 
needed to be checked and fulfilled. These prerequisites are:  
(1) establishing the required experimental setup to perform electrophysiological and 
fluorescence recordings simultaneously in the whole-cell mode, 
(2) studying detailed functional characteristics of three ligands, ACh, nicotine, and 
carbachol at muscle-type nAChRs and comparing them to choose a potential 
candidate for synthesizing its fluorescent derivative,  
(3) testing a newly synthesized fluorescent derivative to study ligand binding and 
channel gating in adult muscle-type nAChRs.  
 
4.1. Establishment of experimental setup 
Typically, cells attached to the chamber bottom are used for performing whole-cell 
recordings. Previously it has been shown that lifted SH-EP1 cells (human epithelial 
cell line) expressing α4β2 AChRs yielded faster desensitization kinetics compared to 
cells attached to the chamber bottom. The authors explained this with a faster 
solution exchange across the cell membrane for lifted cells (Yu et al., 2009).  
For validating this kinetic difference in HEK 293 cells expressing nAChRs, 50 µM of 
ACh (native ligand) was applied via a double-barreled application pipette for 1 s and 
current responses were recorded from lifted and cells attached to the chamber 
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bottom in separate experiments. Normalized current traces of lifted cells and cells 
attached to the chamber bottom is shown in Figure 16A. The mean peak current 
(9.21 ± 2.18 nA, n=5) obtained from lifted cells were similar to the mean peak current 
from cells attached to the chamber bottom (6.91 ± 1.37 nA, n=5; P=0.40). Hence, 
lifting of cells during the measurement did not affect maximum current response 
elicited by the receptor.  
 
 
 
Figure 16. Current responses and kinetics of nAChRs in cells attached to the chamber 
bottom and lifted cells.   
(A) Representative normalized current traces of nAChRs expressed in cells attached to the 
chamber bottom (dark blue) and lifted cell (light blue) showing faster desensitization kinetics 
in the lifted cell. Gray bar represents ligand application period. (B) Representative current 
trace of the lifted cell expressing nAChRs shows current decay fitted with mono-exponential 
function. (C) Representative current trace of cells attached to the chamber bottom expressing 
nAChRs shows current decay fitted with the mono-exponential fit. (D) Time course of 
desensitization kinetics. Data are means ± S.E.M. (n=5), Statistical t-test cell attached to the 
chamber bottom versus lifted cells: **, P ≤ 0.01.  
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Desensitization kinetics were compared by fitting a mono-exponential function to the 
current time courses (Figure 16B,C), yielding time constants of 186.2 ± 21.3 ms (n=5) 
in cells attached to the chamber bottom and 85.4 ± 12.8 ms (n=5; P<0.01) in lifted 
cells (Figure 16D). Hence, desensitization kinetics of the receptor was two times 
faster in lifted cells compared to cells attached to the chamber bottom. The 
accelerated desensitization kinetics supports the idea that the solution exchange was 
more rapid and uniform around lifted cells than around cells attached to the chamber 
bottom. Therefore, all experiments in the present study were conducted on lifted 
cells.  
 
4.2. Selection of the most suitable candidate for cPCF experiments 
In the present study, functional characteristics of ligands, ACh, nicotine, and 
carbamylcholine were investigated and compared to identify the most potential 
candidate for cPCF experiments. Analysis of functional characteristics, such as 
efficacy, potency, and affinity of the ligand was a fundamental step because the 
sensitivity of muscle-type nAChRs varies for different ligands. Since the action of the 
ligand on the receptor depends on two elementary events: affinity and efficacy (PG 
Strange, 2008), the potential candidate for cPCF experiments was sought to be 
chosen on this basis.  
ACh (Figure 17), an ester of acetic acid and choline, is synthesized, stored and 
released by cholinergic neurons at the neuromuscular junction as well as at neuronal 
synapses.   
  
 
 
Figure 17. Chemical structure of ACh  
 
 33 Results 
It is axiomatic that selective binding of ACh at muscle-type nAChRs triggers channel 
activation that arises due to transmembrane conformational changes within the 
receptor protein, followed by a rapid desensitization (Karlin and Akabas, 1995; Grandl 
et al., 2007; Yu KD et al., 2009). This natural agonist is therefore widely used for 
activating nAChRs also in electrophysiological experiments. However, its utility is 
compromised by its susceptibility to hydrolysis (Wonnacott and Barik, 2007). From 
excised patches and single channel studies, it is evident that ACh is a highly 
efficacious agonist at muscle-type nAChR (Dilger and Brett, 1990; Akk and Auerbach, 
1999; Lape et al., 2008). Hence, in the present study focal application of ACh on the 
lifted whole cell containing muscle-type nAChRs was done for determining functional 
properties. 
Nicotine (3 (-)-1-methyl-2-(3-pyridyl)-pyrrolidine), a tobacco alkaloid, is a tertiary 
amine having a pyridine and a pyrrolidine ring (Figure 18). It is a prototypical 
exogenous ligand for both neuronal and muscle-type nAChRs. Nicotine acts on 
ganglionic nerve cells, adrenal medulla cells, at several sites of the central nervous 
system, and on neuromuscular junction (Roger L. Papke, 2014; Mishra et al., 2015). 
It activates and desensitizes all subtypes of nAChRs except two, α9 receptors and 
α9 α10 receptors, where it acts as an antagonist (Wonnacott and Barik, 2007). 
Effects of the nicotine on neuronal nAChRs are well understood (Gourlay and 
Benowitz, 1997; Fenster et al., 1997; Rose et al., 1999, Paradiso and Steinbach, 
2003; Xiu et al., 2009) whereas only a few studies so far investigated nicotinic effects 
on muscle-type nAChRs (Akk and Auerbach, 1999; Jadey et al., 2013). 
 
 
 
Figure 18. Chemical structure of nicotine  
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A comprehensive knowledge about the mechanism underlying the nicotine-induced 
gating of muscle-type nAChRs is still missing, since at muscle-type nAChRs, nicotine 
is described as a weak agonist (Zhou et al., 1999; Akk and Auerbach, 1999), a partial 
agonist (Jadey et al., 2013) or a full agonist (Beene et al., 2002). For this reason, 
macroscopic currents evoked by fast jumps of the nicotine concentration at adult 
muscle-type nAChRs was studied.  
Carbamylcholine or carbachol (2-carbamoyloxyethyl-trimethyl-ammonium chloride) 
(Figure 19) is a choline carbamate formed by substituting the acetyl group with a 
carbamyl group on ACh. This modification makes it a relatively hydrolysis-resistant 
analog (Wonnacott and Barik, 2007). Carbamylcholine imitates the action of ACh and 
thus acts on the parasympathetic nervous system. It has been widely used for the 
treatment of glaucoma and ophthalmic surgeries. It is a non-selective cholinergic 
agonist, which acts on both muscarinic and nicotinic receptors, although more potent 
on muscarinic receptors. Single-channel studies reported that carbachol opens the 
nAChRs ~5 times slower in comparison to ACh (Akk and Auerbach; 1999). Moreover, 
the affinity of carbachol is stated to be 10 times less than ACh (Celie et al., 2004). 
However, carbachol is considered to be a strong agonist at this receptor since it has 
around 1300 times stronger affinity when the receptor exists in the open state in 
comparison to the closed state (Akk and Auerbach; 1999). 
 
 
 
 
Figure 19. Chemical structure of Carbamylcholine  
 
Notably, the presence of a carbamyl group instead of the acetyl group in carbachol 
increases its chemical stability. This might become the key property for reaching the 
main aim in the present study to relate ligand binding to channel gating employing the 
cPCF method. For this reason, the functional properties of carbachol were also 
explored. 
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Since ACh is the native ligand and highly efficacious agonist (Dilger and Brett, 1990; 
Akk and Auerbach, 1999; Lape et al., 2008) at muscle-type nAChRs, the functional 
characteristics of other two candidates, nicotine, and carbachol were compared with 
respect to the ACh in the present study. 
 
4.2.1. Concentration-activation relationships 
The concentration-activation relationship is a well-accepted mean for determining the 
two overall properties of a ligand, potency, and efficacy. These properties are also 
one of the important distinguishing factors for comparing different ligands regarding 
their functionality. 
Sub-saturating concentrations and a saturating concentration of each ligand were 
applied via a double-barreled switch pipette as described earlier (refer 3.4.2). After 
applying one concentration, the cell was kept continuously in the ligand-free control 
solution for about a minute to complete the recovery of the receptor. Representative 
current traces monitored in lifted HEK 293 cells containing muscle-type nAChRs upon 
application of increasing concentrations of ACh, nicotine, and carbachol are shown in 
Figure 20. 
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Figure 20. Activation of muscle-type nAChRs by different concentrations of ACh, 
nicotine, and carbachol. 
Representative traces are demonstrating the inward current monitored from cells containing 
muscle-type nAChRs when varying concentrations of ACh (in red), nicotine (in blue), and 
carbachol (in green) were applied for the indicated time. Gray bar above each trace 
represents the application period of the ligand. 
 
Current obtained at different concentrations of ACh (0.5 µM to 500 µM) and nicotine 
(10 µM to 500 µM) were normalized to their saturating concentration of 500 µM, 
carbachol current responses were normalized to its saturation concentration of 2000 
µM (Figure 21). Mean data points were plotted against each concentration and fitted 
with the Hill function. ACh (EC50=2.5 µM) was found to be about twenty-fold more 
potent than nicotine (EC50=54.5 µM) and about thirty-fold more potent than carbachol 
(EC50=73.2 µM) in activating muscle-type nAChRs at the membrane potential of               
-60 mV. The Hill-coefficient, H, for ACh, nicotine, and carbachol was 1.41,1.36, and 
0.97, respectively.  
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Figure 21. Comparison of concentration-activation relationship of ACh, nicotine, and 
carbachol in muscle-type nAChRs 
Figure 21 shows the comparison of concentration-activation curves obtained for the three 
agonists, ACh, nicotine, and carbachol. Mean values of current responses obtained for the 
three agonists were fitted with the Hill function (Hill fit: red trace-ACh, blue trace-nicotine, and 
green trace-carbachol). When EC50 values were compared, the order of potency obtained is: 
ACh (EC50=2.5 µM; H=1.41) > nicotine (EC50=54.5 µM; H=1.36) > carbachol (EC50=73.2 µM; 
H=0.97). Data are means ± S.E.M. for 4-13 cells. 
 
In whole-cell recording, an attenuation of the peak current due to desensitization may 
lead to an underestimation of the peak currents particularly at higher concentrations 
of ligands and thereby to an underestimation of the EC50 values. Therefore, to correct 
potential artifacts due to the slow ligand application, back extrapolation of the falling 
phase of current was done up to the time point at which the ligand was applied to the 
channels. In this case, the obtained EC50 values for ACh, nicotine, and carbachol 
were 8.57 µM, 88.19 µM, and 114.25, respectively. The estimated Hill coefficient 
values are 0.73, 1.54, and 1.16, correspondingly. 
Upon comparison with ACh, it was found that nicotine is a partial agonist whereas 
carbachol is a full agonist (Figure 22). When 500 µM of ACh and nicotine was applied 
in the same cell, nicotine produced about 58% of the maximum response evoked by 
the ACh whereas (Figure 22A, C) 2000 µM of carbachol produced a similar response 
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as produced by 500 µM of ACh (Figure 22B, C). Hence, ACh and carbachol, both 
were found to be similarly efficacious agonists at muscle-type nAChRs.  
 
 
 
Figure 22. Comparison of the efficacy of ACh, nicotine, and carbachol 
(A) Representative traces obtained by application of 500 µM of nicotine and ACh in the same 
cell. (B) A representative trace of 2000 µM of carbachol and 500 µM ACh in the same cell.     
(C) Efficacy comparison of all three agonists. Here, the data points were obtained by taking 
the ratio of maximum current amplitudes obtained upon application of 500 µM of nicotine and 
ACh in the same cell or 2000 µM carbachol and ACh in the same cell. The blue symbol 
represents the mean data obtained after nicotine application. Open symbols represent 
individual recordings. Green symbol represents mean data for carbachol. Open symbols 
representing individual recordings in case of carbachol are hidden behind the green symbol.                             
(D) Concentration-activation curves with constrained Imax values: 1 for ACh, 0.58 for nicotine, 
and 1 for carbachol. For fit parameters, refer to Figure 21. 
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4.2.2. Comparison of desensitization induced by ACh, nicotine, and carbachol 
in muscle-type nAChRs 
From numerous studies (Katz and Thesleff, 1957; Gross et al., 1991; Elenes and 
Auerbach, 2002, Paradiso and Steinbach, 2003; Giniatullin et al., 2005), it is believed 
that nAChRs undergo desensitization upon a prolonged ligand application. In the 
present study, it was observed that all three ligands desensitized the muscle-type 
nAChRs and that the extent of desensitization as well as the desensitization kinetics, 
depends on the agonist concentration.  
Upon application of varying concentrations of ACh, nicotine, and carbachol, muscle-
type nAChRs elicited a peak current followed by a current decay reaching a transient 
plateau. Desensitization accelerated with increasing concentration of ACh, nicotine, 
and carbachol. The time constant for the current decay upon exposure of various 
concentrations of ACh, nicotine, and, carbachol is reasonably fitted with a mono-
exponential function in most of the cases suggest that there is only one predominant 
desensitized state (Figure 23A-C). In some cases of ACh, the falling phase of current 
was biphasic but was described by a single exponential for simplicity in comparisons. 
 
 
 
Figure 23. Desensitization of muscle-type nAChRs upon application of ACh, nicotine, 
and carbachol   
Representative traces (ACh-red, nicotine-blue, and carbachol-green) showing current decay 
fitted with a mono-exponential function (fit in black) are illustrated. Gray bar above each trace 
indicates application time of the agonist. 
 
To compare the desensitizing effect of all three ligands which work in different 
concentration ranges fairly, the time constants were plotted against the activation 
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level (fraction of activated channels derived from the concentration-activation 
relationship) rather than against the agonist concentration used in this study.  
When time course of desensitization kinetics was compared at low activation levels 
(0.5 µM ACh, 10 µM nicotine, and 10 µM carbachol), it was found that ACh 
desensitized the channel about twice faster than nicotine (τdesensitization for ACh at 0.5 
µM=1090 ms; τdesensitization for nicotine at 10 µM=2437 ms; P=0.0097) whereas almost 
five-fold slower than carbachol (τdesensitization for ACh at 0.5 µM=1090 ms; τdesensitization 
for carbachol at 10 µM=276 ms; P=0.0006). On the other hand, when the comparison 
was done at maximum activation or highest concentration range (500 µM ACh, 500 
µM nicotine, and 2000 µM carbachol), ACh desensitized the channel about four-fold 
faster than nicotine (τdesensitization for ACh at 500 µM=67 ms; τdesensitization for nicotine at 
500 µM=313 ms; P=0.0013) and three-fold slower than carbachol (τdesensitization for ACh 
at 500 µM=67 ms; τdesensitization for carbachol at 2000 µM=26 ms; P=0.0042) (Figure 
24).   
 
 
 
Figure 24. Comparison of desensitization kinetics 
Time course of desensitization versus activation level is plotted in order to compare 
desensitization kinetics of the three ligands. The concentration of ligands at corresponding 
data points is indicated in the graph. At lower activation level, ACh mediated desensitization 
is two-fold faster (P=0.0097) than nicotine while five-fold slower (P=0.0006) than carbachol. 
Additionally, at higher concentrations, desensitization induced by ACh was four-fold faster 
(P=0.0013) than nicotine whereas three-fold slower (P=0.0042) than carbachol. Data are 
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means ± S.E.M. for 4-13 cells. Statistical t-test: P > 0.05=no asterisk, P ≤ 0.05=*, P ≤ 0.01=**, 
P ≤ 0.001=***. 
Extent of desensitization with ACh, nicotine, and carbachol 
The extent of desensitization (ED) of muscle-type nAChRs was determined from the 
steady-state to peak ratio (1-Isteady-state/Ipeak). Mean values of the ED for ACh, nicotine, 
and carbachol were plotted against their respective concentrations and were fitted 
with the Hill equation. In this way, the concentration at which 50% of desensitization 
was reached was estimated. The estimated EC50 for ED for ACh, nicotine, and 
carbachol was 2.5 µM, 21.0 µM, and 2.13 µM and the Hill coefficient H was found to 
be 0.79, 2.02, and 1.04, respectively (Figure 25A-C). In case of carbachol, ED was 
relatively high at low concentrations which might indicate that the high percentage of 
channels underwent desensitization. Estimation of EC50 for ED in case of carbachol 
was based on an extrapolated fitting rather than the fit obtained from data points as it 
was in case of ACh and nicotine because the lowest concentration of carbachol at 
which current measurement was possible was 10 µM. 
 
 
 
Figure 25. Concentration dependence of extent of desensitization 
The graph represents the ED at different concentrations of ACh (red), nicotine (blue), and 
carbachol (green). The ED was boosted with increasing concentrations of indicated ligands. 
EC50 for ED of ACh, nicotine, and carbachol, as well as Hill coefficient, are indicated in the 
respective figures (A-C). Data are means ± S.E.M. for 5-7cells. 
 
For comparison, the ED obtained from the three agonists is plotted against the 
activation level as shown in Figure 26. The ED was compared at lowest 
concentrations (0.5 µM ACh, 10 µM nicotine, and 10 µM carbachol) or at lowest 
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activation level and at saturating concentrations (500 µM ACh, 500 µM nicotine, and 
2000 µM carbachol) or at maximum activation level. At the lowest activation level, the 
ED mediated by ACh is similar to nicotine (ED at 0.5 µM ACh=0.18 ± 0.05 and 10 µM 
nicotine=0.17 ± 0.06; P=0.94) but around five-fold lower than for carbachol (ED at 10 
µM carbachol=0.83 ± 0.02; P=0.0003). On the contrary, the ED is similar at saturating 
concentrations for all three agonists (ACh=0.98 ± 0.005 and nicotine=0.95 ± 0.01; P = 
0.11 and ACh=0.98 ± 0.005 and carbachol=0.99 ± 0.003; P=0.24). This suggests that 
the fraction of desensitizing channels is similar at saturating concentrations. 
 
 
 
Figure 26. Comparison of the extent of desensitization  
Data points obtained after assessment of the ED for all three agonists were plotted as a 
function of the activation level. At the lowest activation level, desensitization mediated by 
ACh is similar (P=0.94) to that of nicotine while approximately five-fold lower (P=0.0003) than 
that for carbachol. Further, at saturating concentrations of agonists, the ED mediated by all 
agonists are similar. Data are means ± S.E.M. for 3-13 cells. Statistical t-test: P > 0.05=no 
asterisk,        P ≤ 0.05=*, P ≤ 0.01=**, P ≤ 0.001=***. 
 
4.2.3. Recovery from desensitization caused by ACh, nicotine, and carbachol 
Recovery of nAChRs from desensitization depends on the type of agonist, its 
concentration as well as on the duration of agonist exposure, which drives the 
receptor into the desensitized state (Reitstetter et al., 199; Wang and Sun, 2005). In 
the present study, recovery from desensitization mediated by ACh, nicotine, and 
carbachol was compared.   
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The time course of recovery from desensitization was estimated using a two-pulse 
protocol, containing a desensitizing pulse (D) and a test pulse. 10 µM ACh was used 
to activate nAChRs because at this concentration large and strong current signals 
were obtained without driving nAChRs into deeper desensitized states, which might 
take several hours to get recovered (Giniatullin et al., 2005). Similarly, 200 µM 
nicotine and 300 µM of carbachol were used to activate receptors since at this 
concentration they showed similar activation as obtained by ACh (see Figure 24). 
After application of desensitizing pulse of 10 µM in case of ACh, 200 µM in case of 
nicotine and 300 µM in case of carbachol, the test pulse of similar concentrations of 
ACh, nicotine, and carbachol (as indicated for desensitizing pulse) were applied after 
various intervals ranging from 0.1-6.5 s (Figure 27A-C). 
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Figure 27. Two-pulse protocol to study recovery from desensitization induced by 10 
µM ACh, 200 µM nicotine, and 300 µM carbachol 
Representative recordings obtained by using a two-pulse protocol to study recovery from 
desensitization evoked by ACh, nicotine and, carbachol are shown. 10 µM ACh, 200 µM 
nicotine and 300 µM carbachol was applied for each desensitizing pulse (D) as well as for 
each test pulse at recovery intervals ranging from 0.1-6.5 s.  
 
There was a waiting period between each pulse pair of at least 30 s to fully recover 
all channels. Current amplitudes of the test pulses were normalized to the current 
amplitude of the respective desensitizing pulses. The relative peak currents (Itest / 
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Idesensitization) were plotted against the interval time and were reasonably fitted with a 
mono-exponential function in case of all the three ligands, ACh, nicotine, and 
carbachol. The time course of recovery (τrecovery) obtained in case of ACh, nicotine, 
and carbachol were 0.3 s, 0.68 s, and 0.25 s, respectively. This suggested that the 
recovery from ACh-mediated desensitization is faster than the nicotine-mediated 
desensitization but slower than the carbachol-mediated desensitization (Figure 28). 
 
 
 
Figure 28. Recovery from agonists mediated desensitization 
Data points obtained by analyzing recovery from agonist-mediated desensitization are plotted 
as a function of concentration. Recovery time constants for ACh, nicotine, and carbachol 
were 0.3 s, 0.68 s, and 0.25 s, respectively. Data are means ± S.E.M. for 3-13 cells. 
 
100 % recovery was not possible in any of the cases. The maximum percentages of 
recovery from desensitization by ACh, nicotine, and carbachol were 95%, 91%, and 
96%, respectively.  
  
4.2.4. Block of nAChRs by ACh, nicotine, and carbachol 
When concentrations (ACh: 2.5 mM and 3 mM; nicotine: 1 mM, 2 mM, and 5 mM; 
carbachol: 7 mM) higher than the saturating concentration of ACh (500 µM), nicotine 
(500 µM), and carbachol (2 mM) were applied to the cells containing muscle-type 
nAChRs, blocking of nAChRs was observed in all cases. In each case, saturating 
concentration as well as concentration higher than the saturating concentration were 
applied in the same cell for better comparison. The peak current amplitude declined 
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noticeably compared to the peak current obtained after application of the saturating 
concentration of ligands. As a result, a bell-shaped concentration-activation curve 
was obtained in case of all three ligands(Figure 29A-C). 
 
 
 
Figure 29. Attenuation in peak current at higher concentrations of ACh, nicotine, and 
carbachol 
Normalized current responses are plotted as a function of indicated concentrations of ACh 
nicotine, and carbachol and fitted with the Hill equation (ACh-red fit, nicotine-blue fit, and 
carbachol-green fit). Bell-shaped concentration-activation relationship indicates blocking of 
the receptor at the concentration higher than the saturating concentration (500 µM in case of 
ACh and nicotine whereas 2 mM in case of carbachol). Data are means ± S.E.M. for 3-12 
cells. 
 
Removal of concentrations higher than saturating concentrations (blocking 
concentrations) of ACh (2.5 mM and 3 mM) and nicotine (1 mM, 2 mM, and 5 mM) 
gave rise to a rapid current increase called ‘off-current’ (Figure 30A), which suggests 
a reopening of channels which were formerly blocked (Maconochie and Steinbach, 
1995). Therefore, the analysis of this off-current can be used to gain information 
about the nature of the block. Surprisingly, no ‘off current’ was observed in case of 
carbachol. 
Experiments were designed to monitor block when different blocking concentrations 
of ligands at different exposure times, i.e. at  200 ms, 1000 ms, 2000 ms, and 5000 
ms and at different membrane voltages (-60 mV & +60 mV) were applied. For 
quantification, the degree of block is calculated as the ratio of the current obtained 
after removal of ligand (Ioff-current) to the current obtained in presence of ligand, (Isteady-
state) (measured just before the washing phase) (Figure 30B). The decline in peak 
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current and a relative increase of the off current of muscle-type nAChRs with 
increasing blocking concentrations of nicotine (2 mM, 3.5 mM, and 5 mM) is shown in 
(Figure 30C).  
 
 
 
 
Figure 30. Block of muscle-type nAChRs at ligand concentrations higher than the 
saturating concentrations 
(A) Representative current trace of nAChRs measured in response to 3.5 mM of ACh 
showing the off-current (red circled) when blocking concentration was washed off. (B) 
Magnification of the current shown in A, focussing on the off current. (C) Current traces 
represent peak current decline and a relative increase in off-current with increasing 
concentrations of nicotine. 
 
Channel block was observed for ACh and nicotine at concentrations higher than the 
saturating concentrations at both -60 mV and +60 mV. Since no off-currents were 
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observed for carbachol at high concentrations at -60 mV, the block was compared for 
ACh and nicotine at -60 mV. The used time points were 200 ms, 1000 ms, 2000 ms, 
and 5000 ms and the concentrations 2 mM, 3.5 mM, and 5 mM (Figure 31). At 200 
ms and at 1000 ms, the degree of block by nicotine is significantly higher than by 
ACh at 3.5 mM and 5 mM whereas there is no difference between the degree of 
block at             2 mM. Similarly, at 2000 ms and 5000 ms the degree of block is 
indistinguishable at the concentrations 2 mM, 3.5 mM, and 5 mM. 
 
 
 
Figure 31. Concentration dependence of block of muscle-type nAChRs by ACh and 
nicotine 
The degree of block is plotted as a function of concentration. At 200 ms, the block by nicotine 
is twice higher than by ACh at 3.5 mM (P=0.02) and 5 mM (P=0.0003). At 1000 ms, the block 
by nicotine is approximately 1.5 times higher than by ACh at 3.5 mM (P=0.04) and 5 mM 
(P=0.006). At 2000 ms and 5000 ms, the difference in the degree of block is insignificant 
amongst agonists. Data are means ± S.E.M. for 3-9 cells. Statistical t-test for ACh versus 
nicotine: P > 0.05=no asterisk, P ≤ 0.05=*, P ≤ 0.01=**, P ≤ 0.001=***. 
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The block by ACh and nicotine (each 5 mM) was also compared at -60 mV and            
+60 mV at different time points, using 200 ms, 1000 ms, 2000 ms and 5000 ms. A 
representative trace of the block by nicotine at both voltages is shown in Figure 32A. 
The block by nicotine is significantly higher than by ACh at -60 mv than at +60 mV at 
all time points (Figure 32B). Reduction of the block has been observed at +60 mV in 
comparison to the block at -60 mV in case of both ACh and nicotine. The voltage-
dependent block was more pronounced for nicotine than for ACh. 
 
 
 
Figure 32. Voltage dependence of block of muscle-type nAChRs by ACh and nicotine 
(A) Representative traces obtained after application of 5 mM nicotine at -60 mV (dark blue) 
and +60 mV (light blue) are shown. (B) Graph showing a comparison of the degree of block 
at -60 mV when 5 mM of ACh (filled red circles) and nicotine (filled blue circles) was applied 
at 200 ms, 1000 ms, 2000 ms and 5000 ms. At 200 ms, 1000 ms, and 2000 ms, block by 
nicotine is approximately two-fold higher than by ACh (P=0.00005, P=0.001, P=0.006, 
respectively), whereas the block by nicotine at 5000 ms is around 1.5 times higher than ACh 
(P=0.01). Block by ACh (void red circles) and nicotine (void blue circles) at +60 mV are also 
represented at  200 ms, 1000 ms, 2000 ms, and 5000 ms. The block by nicotine is 
significantly higher at 200 ms, 1000 ms and 2000 ms (P=0.02, P=0.03, and P=0.006, 
respectively). The difference in the degree of block at 5000 ms is insignificant (P=0.12). Data 
are means ± S.E.M. for 4-5 cells. Statistical t-test for ACh versus nicotine at -60 mV and +60 
mV: P ≤ 0.05=*, P ≤ 0.01=**,               P ≤ 0.00 =***. 
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4.2.5. Comparative chart of functional characteristics of three ligands ACh, 
nicotine, and carbachol 
Comparison of functional properties of muscle-type nAChRs agonists, ACh, nicotine, 
and carbachol are summarized in a tabular form. As mentioned before the functional 
characteristics of nicotine and carbachol were compared with respect to ACh (refer 
4.2).  
 
Table 3: Comparison of functional characteristics of muscle-type nAChRs agonists: 
ACh, nicotine, and carbachol 
Functional 
Characteristics 
 
ACh 
 
Nicotine 
 
Carbachol 
EC50 2.5 µM 54.5 µM 73.2 µM 
H 1.41 1.36 0.97 
Efficacy full agonist partial agonist full agonist 
Desensitization  
at the lowest possible 
activation level 
At 0.5 µM 
τ=1090 ms 
 
At 10 µM 
τ=2437 ms 
 
At 10 µM 
τ=276 ms 
 
Desensitization  
at saturating or at the 
highest activation 
level 
At 500 µM 
τ=67 ms 
 
At 500 µM 
τ=313 ms 
 
At 200 µM 
τ=26 ms 
 
Extent of 
desensitization 
at the lowest possible 
activation level 
0.18 0.17 0.83 
Extent of 
desensitization 
at saturating or at the 
highest activation 
level 
0.98 0.95 0.99 
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Recovery from 
desensitization 
τrecovery=0.3 s τrecovery=0.68 s τrecovery=0.25 s 
Blocking of nAChRs 
by agonist 
attenuation of peak 
current is observed 
at a concentration 
higher than the 
saturating 
concentration 
(500 µM) 
attenuation of peak 
current is observed 
at a concentration 
higher than the 
saturating 
concentration 
(500 µM) 
 
attenuation of peak 
current is observed 
at a concentration 
higher than the 
saturating 
concentration 
(2000 µM) 
 
Concentration-
dependent block of 
nAChRs 
Degree of block  
(Ioff-current/Isteady-state) 
 
 comparatively higher 
than ACh 
not compared 
because no off-
current was observed 
Voltage dependent 
block of nAChRs at   
-60 mV and + 60 mV 
Degree of block  
(Ioff-current/Isteady-state) 
 
 comparatively higher 
than ACh at both      
– 60 mV and  
+ 60 mV 
not compared 
because no off-
current was observed 
 
After comparing the functional characteristics of the three ligands, ACh is considered 
as the most suitable candidate for fluorophore-coupling and application in cPCF 
because it is most potent amongst the three ligands. Whereas ACh activates the 
receptors in a low concentration range, it blocks them in a very high concentration 
range (>500 µM). Apart from this, recovery of the receptor from the ACh induced 
desensitization gets completed within a reasonable time window of 2000 ms. 
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4.3. Selection of linkers for coupling a fluorophore to ACh 
As mentioned under section 3.5, coupling a fluorophore directly to an agonist 
molecule will alter its properties. Hence, coupling a fluorophore to the ligand via a 
linker is a way to minimize the effect of one moiety on the other. Thereby, the 
structure and the length of a linker are crucial factors to be considered (Prescott et 
al., 1999; Shi et al., 2014). Different linkers of variable lengths were tested to find the 
most suitable one for coupling as shown in Figure 33.  
Compounds in which the ester group of the ACh is replaced with an amide group are 
more stable and can be easily synthesized although they are less flexible and 
hydrophilic (Barlow et al., 1978). Therefore, they were considered in the testing 
strategy, although these compounds are expected to be less potential agonists. Two 
linker alternatives were tested: alkyl linkers and PEG linkers. Alkyl linkers were 
expected to be advantageous because it has been reported that when they are linked 
to the functional group, the characteristics of the functional group was not changed 
(Mallavadhani et al., 2014). PEG linkers were considered because they are non-toxic, 
hydrophilic, and highly flexible. 
 
 
 
 53 Results 
 
 
Figure 33. Different linkers coupled to ACh 
Structures and names of the compounds used to identify the most appropriate linker 
chemistry. Chemical structure of acetylcholine is shown in the dotted circle. Acetyl amides 
and acetyl esters were used. 
 
4.3.1. nAChR activation with linker-coupled ACh derivatives 
When linker-coupled ACh (L-ACh) were applied to nAChRs, most of them did not 
produce a current response resembling a typical ACh-induced current. 50 µM of L-
ACh (L-ACh-44, L-ACh-42, L-ACh-30, L-ACh-26, and L-ACh-20) were compared with          
50 µM ACh (Figure 34A-B). Relative current (ILinker/IACh) obtained were 0.04 ± 0.02 (L-
ACh-44), 0.04 ± 0.003 (L-ACh-42), 0.10 ± 0.01 (L-ACh-30), 0.04 ± 0.01 (L-ACh-26), 
and 0.07 ± 0.02 (L-ACh-20). Only L-ACh-30 elicited a current with a desensitization 
kinetics (τ=253.66 ± 36.66 ms) resembling the current elicited by ACh (τ=44.93 ± 1.27 
ms; P=0.40) as shown in Figure 35A-B. Hence, L-ACh-30 was selected for 
fluorophore coupling. However, the amplitude of this current was much smaller 
reaching a value of only 10 ± 1 % of that obtained with ACh.  
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Figure 34. Current produced by nAChRs in response to different L-ACh 
(A) Representative current traces obtained by 50 µM of the indicated L-ACh (in red) and       
50 µM ACh (in black). (B) The relative current obtained from nAChRs in response to 
indicated linkers. Data are means ± S.E.M. for 3-5 cells. 
 
 
 
 
Figure 35. The current response induced by L-ACh-30  
(A) A representative current trace monitored from the cell expressing nAChRs in response to 
50 µM L-ACh-30 (in red) normalized with current obtained in response to 50 µM ACh (in 
black) is shown. Gray bar above the traces indicates application time of ligands. (B) L-ACh-
30 showed similar activation kinetics. Data are means ± S.E.M. for 4 cells. Statistical t-test: P 
≤ 0.05=*. 
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4.3.2. Testing of non-sulfonated Cy3-coupled L-ACh 
Before coupling the L-ACh-30 with a sulfonated Cy3 dye, it was first coupled with the 
non-sulfonated Cy3 to develop the synthesis strategy and to perform the initial 
functional tests. Non-sulfonated Cy3-coupled L-ACh-30 was named herein as L-ACh-
68A. In order to compare the current, 50 µM ACh and 50 µM L-ACh-68A were applied 
in the same cell. Current obtained in response to L-ACh-68A were normalized to the 
current obtained upon ACh application (Figure 36A).  
 
 
 
Figure 36. Current response induced by L-ACh-68A 
(A) Normalized nAChRs current in response to the indicated concentration of ACh and L-
ACh-68A (B) The graph shows the comparison between the time course of desensitization of 
L-ACh-68A (τ=96.05 ms) and ACh (τ=81.5 ms; P=0.23). Mean values are represented by 
black symbols and individual recordings by gray symbols. Similar mean values suggest that 
both agonists desensitize the receptor similarly. Data are means ± S.E.M. for 3-5 cells. 
Statistical t-test: P > 0.05=no asterisk. 
 
Upon comparison, the difference in the time course of desensitization kinetics turned 
out to be insignificant, which indicates that L-ACh-68 A (τ=96.05 ms) desensitizes the 
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receptor similarly as ACh (τ=81.5 ms; P=0.23) (Figure 36B). Hence, obtained 
desensitization kinetics upon application of non-sulfonated Cy3 coupled to L-ACh-30 
(Figure 36A) is more similar to the kinetics of untagged ACh in comparison to the 
desensitization kinetics of L-ACh-30 (τ=253.66 ms) alone (Figure 35A). 
 
Despite the similar desensitization kinetics of currents produced by L-ACh-68A and 
ACh, employment of L-ACh-68A was not feasible because of the lipophilic nature of 
non-sulfonated Cy3 (Figure 37).   
 
 
 
Figure 37. L-ACh-68A coupled with non-sulfonated Cy3 is lipophilic 
(A) Control cell exposed to 10 µM non-sulfonated Cy3-ACh. (B) nAChR expressing cell 
exposed to 10 µM non-sulfonated Cy3-ACh. 
 
Therefore, sulfonated Cy3 was coupled with L-ACh-30 following the same strategy for 
performing cPCF experiments. The new compound synthesized was named as fACh 
or Cy3-ACh (Figure 38). 
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Figure 38. Chemical structure of fACh 
Blue part in the structure represents ACh, red part represents PEG linker, and green part 
represents sulfonated Cy3. 
 
4.4. Relating ligand binding and channel gating using fACh 
4.4.1. Electrophysiological characterization of fACh 
Different concentrations of fACh (0.5 to 500 µM) were applied to the lifted cells 
containing adult muscle-type nAChRs for 1 s to monitor fACh-elicited concentration-
dependent inward currents. Current amplitude increased with increasing 
concentrations of fACh, 500 µM was found to be the saturating concentration (Figure 
39). 
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Figure 39. Concentration-dependent inward currents of fACh 
Representative current traces obtained upon application of indicated concentrations of fACh 
for 1 s is shown. The smallest current response was obtained with 0.5 µM and the maximum 
current response was obtained by 500 µM. 
 
To assure that fACh closely mimics the native ligand ACh, the potency and efficacy of 
fACh was compared with ACh. Varied concentrations of fACh and ACh for 1 s were 
applied to determine the concentration-activation relationship. Peak current values 
obtained for each concentration were normalized to the saturating concentration of   
500 µM in both cases. Mean data points were plotted against each concentration and 
were fitted with the Hill equation (Figure 40A). The estimated concentration of ACh 
which can produce a half-maximal response (EC50) was 2.4 µM and Hill coefficient, H 
was 1.4. The respective values for fACh were 0.99 µM and 1.8. This indicates that 
fACh is twice as potent than ACh. For better comparison of efficacy, the saturating 
concentration of 500 µM of both ACh and fACh was applied in the same cell. Similar 
current responses were obtained from both ligands, suggesting that fACh is similarly 
efficacious as ACh (IfACh,max/IACh,max=0.97 ± 0.1) (Figure 40B). 
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Figure 40. Potency and efficacy of fACh in comparison to ACh 
(A) Relative current versus concentration graph. fACh is twice as potent as ACh. Mean data 
points were plotted against their corresponding concentrations and were fitted with the Hill 
equation. Obtained concentration-response curves of ACh (in black) and fACh (in blue) is 
shown. Upon estimation of EC50 values, fACh (EC50=0.99 µM) was found to be twice as 
potent as ACh (2.4 µM). The Hill coefficient of ACh and fACh was 1.4 and 1.8, respectively. 
Data are means ± S.E.M. for 3-7 cells. (B) fACh and ACh have similar efficacy. Current 
traces obtained upon application of 500 µM ACh and fACh in the same cell is shown. 
 
4.4.2. Establishing cPCF experiments with fACh 
Both fluorescence and electrophysiological recordings were carried out 
simultaneously in cPCF experiments. When applying fACh, a non-specific 
fluorescence signal in the traditional patch-pipettes (pipettes used for 
electrophysiological recordings in this study) that were empty (no cells attached to 
them) was observed. Therefore, there was a need to find the most suitable pipette 
condition that allows for the lowest unspecific fluorescence signal, which would lead 
otherwise to misinterpretation of experimental results.  
Tested pipettes with different glass types and configuration were named as I, II, III, 
and IV (specifications are given in Figure 41B). The protocol of fACh application is 
shown in Figure 41A. Figure 41B represents a comparison of fluorescence intensities 
at three different time points: (a) before application of fACh (b) 50 ms after fACh 
application, and (c) 13 s after fACh application. Glass type ‘IV’ was found to be best 
suitable for further cPCF experiments as it gives the lowest unspecific fluorescence 
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signal in comparison to other glass types. Furthermore, it turned out that avoiding fire-
polishing of the glass pipettes reduced the unspecific fluorescence (Figure 41C). 
 
 
 
Figure 41. Comparison of patch pipettes with different glass types and configuration 
(A) Application protocol of fACh (B) Indicated glass types having indicated configurations (I-
IV) were tested to find the most suitable glass pipette for cPCF experiments. Graphs 
representing fluorescence intensity at three-time points: before application of fACh, 50 ms 
after application and 13 s after application (wash-out phase). Glass type IV is best suitable 
for further cPCF experiments as it produced the lowest signals. Transfected cells caused a 
signal of ~10 a.u. under the same conditions (for comparison see Figure 43). (C) Fire-
polishing caused even higher non-specific fluorescence signal. The glass used was 
borosilicate having inner diameter 1.12 mm and outer diameter 1.5 mm. Pipette resistance 
was between 1 to 3 MΩ.  
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4.4.3. fACh binding to muscle-type nAChRs 
To check if fACh is able to bind to muscle-type nAChRs, 10 µM fACh was applied to 
transiently transfected HEK 293 cells attached to the cell culture coverslip used for 
cultivation. A pronounced membrane staining only in cells carrying the receptor was 
found. To identify transfected and non-transfected cells cytosolic CFP was used as a 
transfection marker. Thus, fACh was found to bind to nAChRs (Figure 42). 
 
 
 
 
 
 
Figure 42. fACh binds to nAChRs 
The confocal image represents binding of fACh (fluorescent signal) only to the cell 
expressing nAChRs (in this case stained blue because of CFP was used as a transfection 
marker). All other cells appearing in black are control cells because they do not express the 
receptor. 
 
To study the reversibility of fACh binding, washing-in and washing-out experiments 
on lifted control cells and transfected cells were performed. As shown for cells 
attached to the chamber bottom (Figure 42) high fluorescent signals were obtained 
only in case of transfected cells whereas in control cells fluorescence signals were 
negligible (Figure 43A). Upon washing, the intensity decreased. These results 
indicate reversibility of the signal, thus of ligand binding (Figure 43B). 
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Figure 43. Fluorescence intensity increases due to binding in transfected cells 
(A) fACh yielded a fluorescence signal after binding to adult muscle-type nAChRs in HEK 293 
cells which are absent in control cells. Red fluorescence in the non-transfected cell arose 
from the background dye Dy647, which is used to identify the position of the cell and for 
background subtraction (see Materials and Methods). (B) Graphs representing the specificity 
of the fluorescence signal obtained 50 ms (left panels) and 12 s (right panels) after switching 
from 10 µM fACh to control solution, respectively. Quantification was done in the washing out 
phase to get rid of the background signal caused by unbound fACh. Data points represent 
individual recordings (n=3 for controls, n=2 for transfected cells). 
 
4.4.4. PCF applications using fACh  
Two different protocols (I and II) were used for measuring fluorescence signals after 
application of fACh (Figure 44): Protocol I had a scan time of 100 ms and a high 
sampling rate (10 Hz). Protocol II had a scan time of 800 ms and a lower sampling 
rate of 1.3 Hz. Lower sampling rate provides an advantage of increased scan time 
per image that ultimately yields an increased number of pixels. Hence, better image 
resolution can be obtained. Protocol I was applied for washing-in and protocol II for 
washing-out fACh (Figure 44). 
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Figure 44. Protocols for fluorescence signal measurements 
Two protocols were used to monitor fluorescence signals. Protocol I was used for washing-in 
and protocol II for washing-out. Green symbols represent the time course of the fluorescence 
intensity in a transfected cell (mean of 4 traces of the same cell). Grey symbols represent a 
respective time course in a control cell. 
 
After confirming that fACh mimics the agonistic behavior of native ACh binding to 
muscle-type nAChRs in a specific and reversible way and defining the experimental 
settings, started to test whether fACh is useful to study nAChR gating was tested. 
Application 1: Monitoring the kinetics of agonist binding and unbinding 
10 µM fACh was applied to transfected cells to monitor binding as well as unbinding. 
Both the binding and unbinding process could be reasonably fitted with a bi-
exponential function. Initial fast components of binding as well as unbinding were too 
fast to be resolved at a sampling rate of 10 Hz. Nevertheless, the slower phases 
could be described more thoroughly, yielding a time constant for the slow component 
of binding of 286 ± 81 ms and for the slow component of unbinding of 1652 ± 323 ms 
(Figure 45). 
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Figure 45. fACh binding and unbinding follow bi-exponential time course 
fACh binding and unbinding to the nAChR. The data points of four traces were averaged. In 
protocol I, faster events were not resolved at a sampling rate of 10 Hz. In protocol II, the 
sampling rate was set to 1.3 Hz.  
 
Application 2: Relating agonist binding to desensitization 
Upon application of 10 µM fACh, a steep increase in the fluorescence intensity was 
followed by a slow phase approximating a constant value. This slow binding 
component might reflect that the receptor enters into the desensitized state. 
Concerning the current, the falling phase (desensitization), recorded simultaneously 
with fluorescence recording, could also be reasonably described by a bi-exponential 
function and it turned out that the time course of the slow component of 
desensitization (τslow, desensitization=356 ± 26 ms) was similar to that of binding (τslow, 
binding=286 ± 81 ms). Figure 46 shows an overlay of current trace (inverted) and 
fluorescence signal to demonstrate this kinetic similarity. 
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Figure 46. Slow phase of the fluorescence increase is similar to the slow phase of 
desensitization 
Superposition of fluorescence (green) and a current signal (blue). The slow component of 
fluorescence increase (τslow, binding=286 ± 81 ms) and slow component of current 
desensitization (τslow, desensitization=356 ± 26 ms) show similar kinetics. Data are mean ± 
S.E.M. of 4 traces. 
 
Application 3: Relating ligand unbinding to recovery from desensitization 
The time course of the unbinding phase of fACh and time course of the recovery from 
the ACh mediated desensitization were compared to investigate if recovery from 
desensitization correlates with agonist unbinding. It turned out that the slow 
component (τslow, unbinding) of unbinding (τ=1652 ± 323 ms) (refer Figure 46) was much 
slower than the time course of recovery from desensitization (τ=300 ms) (refer Figure 
28 for ACh). This suggests that the recovery from desensitization is independent of 
the dissociation of at least one agonist molecule from the receptor. 
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5. Discussion 
The muscle-type nAChR is one of the best-studied cell surface receptors. It is 
involved in synaptic transmission at the neuromuscular junction (Kistler et al., 1982; 
Stroud and Moore, 1985) and served as an archetype for a better understanding of 
allosteric mechanisms of ligand-gated ion channels (Changeux, 1990; Prince and 
Sine; 1999). Several classical biophysical methods such as crystallography, electron 
microscopy, electrophysiology, ion flux assays, ligand-binding assays, and single-
channel recordings have provided deep insight into structure and function of this 
receptor but the knowledge about their interrelationship is relatively poor (Karlin, 
2002; Lester, 2014). There are several questions which are still to be answered, such 
as whether binding of a ligand at one binding site can open the channel or both 
binding sites are needed to be occupied, or whether there are intermediate states 
when the receptor proceeds through electrophysiologically defined states (closed, 
open and desensitized states). Various complex kinetic models have been proposed 
so far to unravel the state-dependent relationships, but most of them are based on 
indirect information about binding. Experimentally obtained binding data could 
validate existing kinetic models or lead to new ones. 
New fluorescence approaches, such as time-resolved photolabeling (Averalo et al., 
2005), use of fluorescent unnatural amino acids (Nowak et al., 1995), fluorescent 
ligands (Grandl et al., 2007, Krieger et al., 2008; Fujimoto et al., 2008; Schmauder et 
al., 2011) or fluorophore-coupled receptors (Dahan et al., 2004) in combination with 
electrophysiology provided new insights into the state-dependent relationships but a 
clear concept is still missing. The present study is intended to contribute to a better 
understanding by modifying and using a confocal patch-clamp fluorometry (cPCF) 
technique (refer to 5.1) to study agonist binding and activation behavior 
simultaneously. Using a fluorescent agonist and the whole-cell configuration has 
provided an advantage to directly monitor state-dependent ligand binding under best 
possible physiological conditions, without relying on any structural modifications of 
the receptor. 
 
5.1. Newly modified cPCF technique 
Until now, PCF (Zheng and Zagotta, 2000) or cPCF has been used in combination 
with excised Xenopus laevis oocytes patches in the inside-out configuration to study 
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state-dependent conformational changes and ligand binding in CNG, and HCN 
channels (Biskup et al., 2007; Kusch et al., 2012) and in the outside-out configuration 
to study channel gating in BASIC channels (Schmidt et al., 2014). In the present 
study, this technique was modified to study ligand binding to an extracellularly 
controlled ion channel in the whole-cell configuration.  
The outside-out configuration could have been an alternative for studying ligand 
binding to extracellular binding sites. This possibility was ruled out because HEK 293 
cells were chosen as a heterologous expression system, which would allow only 
small patches with a low fluorescence and current signal. As this technique demands 
high signal to noise ratio, it was decided to collect data from whole cells in the 
present study.  
The mammalian HEK 293 cell line has been chosen as a heterologous expression 
system over non-mammalian cells (Xenopus laevis oocytes) though those cells are 
reported to be more advantageous in terms of expression level and in providing a 
suitable environment for proper maintenance of physiological functions (Korngreen, 
2016). Additionally, differences in channel properties of nAChRs expressed in 
oocytes compared to those expressed in mammalian cells have also been reported 
(Grassi et al., 1995; Sivilotti et al., 1997; Lewis et al., 1997; Millar, 2009). 
The experiments were done on lifted cells rather than on cells attached to the 
chamber bottom after attainment of the whole-cell mode because faster 
desensitization kinetics was observed in lifted cells (85.42 ms) in comparison to the 
desensitization kinetics of cells attached to the chamber bottom (186.24 ms). Hence 
results support the idea proposed by Yu and coworkers in 2009 that application of 
ligand solutions to lifted cells results in homogenous and faster solution exchange.  
Besides that, a specific glass pipette (Borosilicate glass inner diameter:1 mm; outer 
diameter: 1.5 mm) was used for cPCF experiments because other glass pipettes 
(different glass types and configurations; refer 4.4.2 for details) produced more non-
specific fluorescence upon ligand application. In earlier cPCF studies with excised 
patches, the fluorescent signal was estimated from the patch that lies inside the patch 
pipette rather than at the very tip, therefore, glass type and configuration was not a 
major issue. Further, fire polishing of the pipette was also avoided in the present 
study because it increased the non-specific fluorescence signal. The reasons for this 
phenomenon are not clear.  
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5.2. Selection of a potential agonist for cPCF experiments 
For relating ligand binding and channel gating of nAChR using cPCF experiments, 
the prerequisite was to synthesize a fluorescence agonist that could closely mimic the 
properties of the native ligand ACh. To choose the most suitable candidate for 
fluorophore coupling, the electrophysiological characteristics of three unmodified 
agonists, ACh, nicotine, and carbachol, under whole-cell conditions, which includes 
the concentration-activation relationship, the desensitization behavior and the ability 
to block the channel were compared first. ACh was chosen because it is the native, 
highly efficacious agonist of muscle-type nAChRs (Dilger and Brett, 1990; Akk and 
Auerbach, 1999; Lape et al., 2008). Nicotine, a plant alkaloid is the name-giving 
agonist of the nAChR as its primary target and was, therefore, an interesting agonist 
to be studied. Carbachol is a synthetic choline ester and a strong agonist (Akk and 
Auerbach, 1999). It is chemically more stable than ACh because of the presence of a 
carbamyl group instead of an acetyl group (Wonnacott and Barik, 2007). 
 
5.2.1. Potency and efficiency of the potential candidates 
The concentration-activation relationships of the three ligands were compared to 
determine the most potent and most efficient agonist amongst them. Upon 
comparison, ACh was found to be most potent. It was twenty-fold more potent than 
nicotine and thirty-fold more potent than carbachol. Further, ACh and carbachol have 
similar efficacy, while nicotine could produce only 58% of the maximum current 
produced by ACh at 500 µM. Hence, results support previous reports showing that 
ACh and carbachol are full agonists whereas nicotine is a partial agonist for the 
receptor (Dilger and Brett, 1990; Akk and Auerbach, 1999, Jadey et al., 2013, Celie 
et al., 2004). However, nicotine was also considered as a full agonist at muscle-type 
nAChRs in an earlier study (Beene et al., 2002). 
In previous studies, the estimated EC50 values of ACh (via single-channel, whole-cell 
or excised patch studies) at muscle-type nAChRs range between 7- 28 µM (Dilger 
and Brett, 1990; Cooper et al., 1996; Akk and Auerbach, 1999; Brownlow et al., 2001; 
Hatton et al., 2003; Jonosson et al., 2006, 2009; Papke et al., 2010). However, in the 
present study, a smaller EC50 of 2.49 ± 0.15 µM was found. Reasons behind varying 
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EC50 values might be the use of different techniques, particularly the method of ligand 
application. 
For whole-cell recordings, it is assumed that due to the agonist application time 
slower than the time needed for channel activation, the peak current might be 
compromised by the fast onset of desensitization superimposing with activation. 
Maconochie and Steinbach (1995) proposed a back-extrapolation method for the 
peak-reduction correction. However, they found that back-extrapolation will lead to an 
overestimation of the data. In this study, back-extrapolation of the falling phase of the 
current using exponential function until the time point at which ligand was applied was 
also done. When mean data points obtained after extrapolation were fitted with the 
Hill equation, a slight right shift of the concentration-activation curve was found. The 
corrected EC50 value for ACh (8.57 µM) was around four-fold higher than the 
empirically obtained EC50 value (2.4 µM). The Hill-coefficient, H, obtained before and 
after correction was 1.41 and 0.73, respectively. Thus, the true EC50 value of ACh is 
expected to lie between 2.4 µM and 8.57 µM.     
In case of nicotine and carbachol, to the best of our knowledge, the concentration-
activation relationships were not deduced for muscle-type nAChRs from whole-cell 
configuration till date. Herein, an EC50 value for nicotine of 54.5 µM; H = 1.36 and for 
carbachol of 73.2 µM; H= 0.97 was found. Interestingly, these values were also lower 
than the previously reported values estimated by single-channel recordings (Akk and 
Auerbach, 1999; Marshall et al., 1991). Single-channel studies have reported EC50 
values for nicotine ranging from hundreds of micromolar to even millimolar range 
(Yost and Winegar, 1997; Akk and Auerbach, 1999; Jadey et al., 2013). EC50 for 
carbachol is laying in hundreds of micromolar range (Marshall et al., 1991; Akk et al., 
2005). After correction by back-extrapolation in case of nicotine and carbachol, 
slightly higher EC50 value were estimated (EC50 nicotine = 88.19 µM; EC50 carbachol = 
114.25 µM). The obtained Hill coefficient, H after extrapolation for nicotine and 
carbachol was 1.54 and 1.16 respectively. In comparison to ACh, only slight increase 
in the extrapolated EC50 values for nicotine and carbachol led to suggest that the 
rising phase of the current in case of nicotine and carbachol were only slightly 
compromised by desensitization. This was unexpected because knowledge about the 
desensitization behavior obtained herein would suggest a higher effect of 
desensitization on the peak current for carbachol and a similar effect for nicotine 
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compared to ACh (see next paragraph). Further experiments are needed to solve this 
discrepancy. 
Regarding the usability of PCF recordings, the comparison of potency and efficacy 
makes the native ACh the most suitable candidate amongst the three tested ligands 
for fluorophore coupling because it would require the lowest concentrations range.  
 
5.2.2. ACh, nicotine, and carbachol-induced desensitization in muscle-type 
nAChRs 
To study the agonist-mediated desensitization kinetics, the falling phase of the 
current was fitted with an exponential function. For all three ligands, the current was 
best fitted with a mono-exponential function indicating the presence of at least one 
predominant desensitized state. Desensitization mediated by ACh and nicotine were 
fast and found to be similar whereas carbachol-induced desensitization was fastest of 
all. This supports a previous study showing that carbachol mediated-desensitization 
of muscle-type nAChRs is much faster than ACh-mediated desensitization in BC3H-1 
cells in out-side out patch (Dilger and Liu, 1992). 
Some studies reported one or two possible components of desensitization time-
course (Dilger and Liu, 1992; Paradiso and Brehm, 1998; Jahn et al., 2001) while four 
to five components of desensitization time-course were also reported (Elenes and 
Auerbach, 2002). However, the number of intermediate states of desensitization 
remains still unclear (Figure 47) (Reitstetter et al., 1999).   
Paradiso and Brehm (1998) interpreted the reason behind the mono-exponential time 
course of desensitization. According to them, receptors first accumulate in a ‘shallow 
state’ of desensitization before entering into deeper states, therefore, the transition 
into the other states is electrically silent and cannot be predicted. 
Also, the ED (1-Isteady-state/Idesensitization) differed for the three agonists. At lower 
concentrations of agonists (0.5 µM ACh, 10 µM nicotine, and 10 µM carbachol) or at 
the lowest percentage of activation (refer 4.2.2 for details) the ED was observed to be 
similar in case of ACh and nicotine (fraction of channels which underwent 
desensitzation: 0.5 µM ACh = 0.18 ± 0.05 and 10 µM nicotine = 0.17 ± 0.06) whereas 
it was observed to be 5-times higher in case of carbachol (fraction of channels which 
underwent desensitization: 0.83 ± 0.02). However, the ED was observed to be similar 
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at saturating concentrations of all three agonists or at maximum activation 
percentage of all agonists (fraction of channels which underwent desensitization: 500 
µM ACh = 0.98 ± 0.005, 500 µM nicotine = 0.95 ± 0.01, and 2000 µM carbachol = 
0.99 ± 0.003). To describe the concentration dependence of the ED, the Hill equation 
was fitted to the data. It was found that EC50 for ED for ACh (2.5 µM) and for 
carbachol (2.12 µM) were similar and significantly lower than for nicotine (21.0 µM).  
 
 
 
Figure 47. A simple model showing different states of desensitization of nAChRs. 
In this kinetic model, ‘C’ represents the closed state, ‘O’ represents the open state and D1 to 
Dn represent n intermediate states of desensitization (adapted from Reitstetter et al., 1999). 
 
Interestingly, the concentration at which half of the channel population gets activated 
and the concentration at which half of the channel population underwent 
desensitization in case of ACh was similar. However, this was not the case for 
nicotine and carbachol. The EC50 for ED is 2.12 µM for carbachol supported 
previously reported values (Feltz and Trautmann, 1980).   
The data about desensitization kinetics and ED support the idea that desensitization 
behavior depends on the type of agonist which drives the channel into desensitization 
(Reitstetter et al., 1999; Giniatullin et al., 2005). Carbachol caused the fastest 
desensitization and was able to drive a high fraction of the channel population into 
desensitization even at very low concentrations. Nicotine and ACh behaved very 
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similar regarding their ability to desensitize, however, nicotine needed a higher a 
concentration to drive the receptor to the same extent. 
Recovery from desensitization of muscle-type nAChRs mediated by the three 
agonists was monophasic. Recovery from carbachol-mediated desensitization was 
faster (τrecovery = 0.25 s) than from ACh and nicotine-mediated desensitization (τrecovery 
= 0.30 s, τrecovery = 0.68 s, respectively). After providing maximum time-interval of 6.5 s 
for recovery, the fractions of channels that got recovered were ~95%, ~91%, and 
~96% for ACh, nicotine, and carbachol respectively. 
Several studies reported that recovery of muscle-type nAChRs from agonist-mediated 
desensitization is independent of the nature of the agonist (Katz and Thesleff, 1957; 
Feltz and Trautmann, 1982) whereas other studies reported that rates of recovery 
from agonist mediated-desensitization depend on the nature of agonists that drives 
the receptor into the desensitized state as well as on the exposure time of agonists 
(Dilger and Liu, 1992; Reitstetter et al., 1999).  
Regarding the time-course of recovery, one study reported monophasic time courses 
(Dilger and Liu, 1992) of muscle-type nAChRs while another reported biphasic 
recovery (Paradiso and Brehm, 1998). It is speculated that the reason behind the 
monophasic recovery, in this case, is due to the electrically silent deeper desensitized 
states and the presence of only one prominent desensitized state. Fractional 
percentage of recovery from the ACh, nicotine, and carbachol mediated 
desensitization also supports the fact that some percentage of channel went under 
deeper desensitization and might take longer time periods to get fully recovered. 
It is noteworthy that carbachol rapidly and strongly desensitizes the receptor even in 
a low concentration range, albeit desensitized receptors recover very quickly from 
carbachol mediated desensitization. For the purpose of studying the relationship 
between agonist binding and receptor desensitization, all three agonists tested are 
interesting candidates because desensitization is well pronounced in all of them.  
 
5.2.3. Acetylcholine and nicotine-induced channel block 
Block of muscle-type nAChRs by agonists of the receptor is due to rapid self-
antagonism that has been ascribed to a mechanism in which agonists occludes the 
ion channel pore if present in a concentration higher than the saturating concentration 
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(Sine and Steinbach, 1984; Maconochie and Steinbach, 1995). Additional binding to 
binding sites elsewhere than in the αδ and αε binding sites would be a major problem 
for fluorescence binding studies. Therefore, it was required to test in which 
concentration range a channel block has to be expected for the three candidates.   
After application of high concentrations (above saturating concentrations) of the three 
agonists, off-currents (current monitored in wash-out phase due to reopening of the 
channels which were formerly blocked during application phase) were recorded at a 
transmembrane voltage of -60 mV in case of ACh and nicotine only. In case of 
carbachol, off-currents were not observed even at a very high concentration of 7 mM 
and hence, it might be interesting for future research.  
To describe the blocking behavior in more detail, the degree of block at different 
concentrations (concentration range: 2 mM to 5 mM), different application times (200 
ms to 5000 ms) and different voltages (-60 mV and +60 mV) were estimated. The 
block induced by nicotine is concentration dependent, whereas block by ACh was not 
in the concentration range tested herein. Both ACh and nicotine block were observed 
to be time-independent within the range tested (200 ms to 5000 ms) in the present 
study but have a strong dependence on voltage.  
From the appearance of off-currents only at concentrations higher than the lowest 
saturating concentration, it is concluded that for binding studies additional binding of 
the agonist to a binding site within the channel pore should not be a major issue 
because the lowest saturating concentration can be chosen for the experimental 
settings. 
 
5.3. Relating ligand binding and channel gating using fACh 
Fluorophore-coupled agonist molecules are well suitable tools to study ligand binding 
to receptor binding sites by directly measuring their emission intensities using 
fluorescence microscopy approaches (Biskup et al., 2007; Kusch et al. 2010; 
Schmauder et al., 2011; Bhargava et al., 2013). An important prerequisite is a 
fluorophore and a coupling strategy, which does not negatively affect the agonist's 
behavior. 
Since the early 70’s of the last century, attempts were made to couple fluorophores 
such as dansyl (Cohen and Changeux, 1973; Waksman et al., 1980) and pyrene 
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(Barrantes et al., 1975), N-7(4-nitrobenzo-2-oxa-1,3-diazole) (Jürss et al., 1979) to 
the native ligand ACh and its analogs. However, the applicability of these fluorescent 
compounds was not well-suited for fluorescence studies, such as cPCF, because 
they either yielded fluorescent antagonists after fluorophore coupling or weak 
fluorescent agonists with moderate affinities (Waksman et al., 1980; Jurss et al., 
1979). Also, some fluorescent agonists had a short fluorescent lifetime or an 
inappropriate emission wavelength (Fujimoto et al., 2008). In 2008, Fujimoto and 
colleagues reported the synthesis of a fluorescent derivative called Cy3-acylcholine, 
with Cy3 as the fluorophore showing significantly improved biophysical features. 
However, the yield of this synthesis was very low, about 0.06% (Wu et al., 2009). 
Also, Krieger and co-workers in 2008, reinvestigated pharmacological properties of 
previously synthesized fluorescent acylcholines, as well as, newly synthesized 
fluorescent acylcholine by them, were also investigated on embryonic nAChRs. The 
fluorescent acylcholine compounds either gave no or lower responses than 
unmodified ACh.  
As an alternative, agonists other than ACh were chemically modified. In 2007, Grandl 
and colleagues synthesized five fluorescent analogs of the agonist epibatidine where 
it was either fluorescently tagged by coumarin dye, Atto dye or cyanine dye (EPB-
Cou, EPB-Cl-Cou, EPB-Atto610, EPB-Cy3, and EPB-Cy5). In 2011, Schmauder and 
co-workers used epibatidine-Cy5 to study activation kinetics in muscle-type nAChRs 
at the single molecule level. However, use of epibatidine-Cy5 was avoided in this 
study because Grandl and colleagues (2007) have reported that the affinity of 
fluorescent derivatives of epibatidine for muscle-type nAChRs was decreased by 
three orders of magnitude in comparison to the untagged epibatidine. Apart from this, 
epibatidine has reverse site selectivity, i.e., unlike native ligand ACh, epibatidine 
binds more tightly to the αε binding site than to the αδ site (Prince & Sine, 1999; 
Dahan et. al, 2004).  
For this reason, in the present study, it was intended to synthesize and test a newly 
synthesized fluorophore-coupled ACh (fACh) in cPCF experiments. The syntheses 
were realized in cooperation with the Plested lab (FMP Berlin), ChiroBlock GmbH 
(Wolfen, Germany) and Abcam (Cambridge, UK). At first, (through electrophysiology) 
several ACh-derivatives modified by different chain-like structures to serve in the next 
synthesis step as linkers between ACh and fluorophore (L-ACh) were tested. A PEG 
linker was found to be more appropriate in electrophysiological experiments than 
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alkyl linkers. A second interesting observation was the dependence of functional 
properties on the length of the linker. The longer the length of the linker, the lower 
was the current signal. A correlation of the pharmacological features and the length 
and structure of the linker was described before (Krieger et al., 2008). 
In the next step, a non-sulfonated Cy3 was coupled to this ACh-linker derivative (L-
ACh-68A). L-ACh-68A was used to optimize the synthesis strategy and to perform the 
first electrophysiological experiments. Coupling the dye improved the functional 
properties compared to derivatives just carrying the linker alone.   
After having confirmed that the test compound L-ACh-68A is able to activate the 
channel, Cy3-ACh (fACh) was synthesized following the same strategy. Before 
applying newly synthesized fACh in cPCF experiments, the ability to activate muscle-
type nAChRs was examined by patch-clamp experiments and was compared with 
ACh. Upon application of successive concentrations of fACh, increase in current 
amplitudes was monitored. When fACh was compared with untagged ACh, fACh was 
found to be similarly efficient as ACh. Additionally, fACh is twice as potent as ACh. 
Interestingly, similar results were also found by Grandl and co-workers in 2007 in 
case of epibatidine that was coupled by Cy5. Epibatidine-Cy5 was also found to be a 
full agonist as epibatidine but twice as potent as epibatidine at muscle nAChR (gain 
of function mutant of δS268K).  
After confirmation that fACh is a suitable agonist at muscle-type nAChR, it was used 
in cPCF experiments. Herein, the usage of fACh for three different applications has 
been proposed: 
 
Application 1: Monitoring agonist binding and unbinding 
Using a fluorescently tagged ACh in combined fluorescence and electrophysiological 
recordings is a suitable tool to study agonist binding and unbinding while 
simultaneously monitoring the channel activity. Upon both washing in and washing off 
fACh, two components in the fluorescent signal was found. The fast components in 
both processes were too fast to be resolved under the technical conditions. However, 
the slow processes could be analyzed. A slow component of binding of 286 ± 81 ms 
and a slow component of unbinding of 1652 ± 323 ms was found.    
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It is speculated that the two components of the unbinding kinetics might reflect 
different affinities of the two binding sites, αδ and αε, as reported earlier on the basis 
of electrophysiological data (Arias, 2000; Unwin, 2005; Kalamida et al., 2007; 
Wonnacott and Barik, 2007) or time-resolved fluorescence spectroscopic data 
(Martinez et al., 2000). The fact that these two components cover around 50% each 
is supporting this idea. However, it cannot be ruled out that two different channel 
population exist, showing a fast and a slow unbinding behavior. Future experiments 
employing mutated receptors with only one functional binding sites or application of 
site-specific blockers to wildtype receptors could help gaining more insights into this 
problem. 
 
Application 2: Relating agonist binding to desensitization 
Because PCF allows for simultaneously measuring agonist binding and activation 
levels of the channel, fACh can be used to study desensitization-dependent agonist 
binding. Relating agonist binding and activation was not possible with the approach 
used herein because both activation and the first phase of binding were too fast to be 
resolved. 
Like the fluorescence signal, the simultaneously recorded current trace was also 
reasonably fitted with a bi-exponential function. The slow phase of binding (τbinding, slow 
= 286 ± 81 ms) and slow phase of desensitization (τdesensitization, slow = 356 ± 26 ms) 
were found to be similar. The similarity in the time course of desensitization (slow 
component) and time course of binding (slow component) supports the idea reported 
earlier on the basis of patch-clamp experiments that the binding affinity increases 
during desensitization (Elenes et al., 2006). 
 
Application 3: Relating unbinding to recovery from desensitization 
Furthermore, fACh can be used to study recovery from desensitization. The time 
course of recovery (τrecovery = 300 ms approx.) of muscle-type nAChRs was compared 
from ACh-mediated desensitization and the slow component of unbinding of fACh 
(τunbinding, slow = 1652 ± 323 ms). Recovery from desensitization is five times faster than 
agonist dissociation from one of the two binding sites. From this, it can be speculated 
that the remaining bound ligand is not involved in the recovery from desensitization 
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as the desensitization is already completed and a new activation process can be 
started. 
In these experiments, untagged ACh was used in lieu of fACh for recovery 
experiments because of cost-effectiveness. The fact that fACh is twice as potent as 
ACh cannot be neglected when evaluating this application. For better comparison, 
future experiments using fACh instead of ACh to study the recovery time course 
would help to study this relationship even more thoroughly.  
Although fACh is a suitable tool for relating ligand binding and channel gating in 
whole-cell configuration, a major limitation is its chemical instability in solution. 
Performing experiments immediately after dissolving fACh in the buffer may 
overcome this problem. The reason for the instability is the acetyl group which is 
prone to hydrolysis (Wonnacott and Barik, 2007). The carbamate group of carbachol 
is more stable (Wonnacott and Barik, 2007); hence, fluorescent derivatives of 
carbachol can be used in cPCF experiments to unravel functional aspects of nAChR 
gating. Additionally, a fluorescent derivative of carbachol might be useful for studying 
functions of muscarinic receptors because carbachol is a potent agonist to muscarinic 
ACh receptors as well (Wonnacott and Barik, 2007).  
Despite various advantages of cPCF, the experimental demand for sampling rate 
higher than 10 kHz to resolve faster components of binding and unbinding of fACh 
limits its application. Although higher sampling rates can be achieved, resolution of 
the captured image will be compromised in this case. Photon counting is a potential 
alternative to this problem; however, this approach does not offer a strategy to 
subtract the signal of unbound ligands from the membrane-bound ligands. Although 
every method has some advantages and pitfalls, direct monitoring of agonist binding 
using cPCF allows for direct investigation of ion channel functions that are so far 
basically relying on electrophysiological data. It can provide new information to shed 
light on the complex nAChR gating behavior. 
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6. Conclusions 
In the present study, the cPCF technique was used to investigate functional 
properties of muscle-type nAChR in real time. Electrophysiological properties of the 
agonists, i.e. nicotine and carbachol were compared with the properties of the native 
ligand ACh to find the most suitable ligand for synthesizing its fluorescent derivative. 
Surprisingly, concentration-activation curves for nicotine and carbachol in whole-cell 
configuration for muscle-type receptors was derived for the first time in the present 
study. In comparison to the previous data obtained from single-channel studies, lower 
EC50 values for all the three agonists were estimated in the present study. 
Additionally, it was also found that nicotine is a partial agonist but carbachol is a full 
agonist. Both agonists are moderately potent at this receptor. 
ACh was found to be the most efficacious and potent agonist at this receptor in 
comparison to nicotine and carbachol. Therefore, ACh was selected for synthesizing 
its fluorescent derivative and named it ‘fACh’. By using fACh, cPCF experiments were 
performed for the first time in the whole-cell configuration in the present study to 
study muscle-type nAChRs functions. 
As a result, it was found that both binding and unbinding of agonist to the receptor is 
a biphasic process which supports the previously proposed idea based on 
electrophysiological data that the two binding sites have different affinities. The time 
course of the increase in fluorescent signal due to binding was found to be similar to 
the slow phase of desensitization which was recorded simultaneously with 
fluorescence recordings. The observations corroborate the previous result that during 
desensitization, the affinity of the receptor for the ligand increases.  
Hence, the feasibility of synthesis and employment of fluorescence agonists to shed 
light on the functionality of nAChRs and Cys-loop superfamily, without affecting the 
receptor by genetic or chemical fluorophore tagging has been successfully 
demonstrated in the present study. Apart from ACh, fluorescent derivatives of nicotine 
and carbachol can also be synthesized for fluorescence studies. Though nicotine and 
carbachol activate nAChRs competitively in a higher concentration range than ACh, 
both can be used for wash-out unbinding experiments. 
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